WO2005056801A1 - Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation - Google Patents

Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2005056801A1
WO2005056801A1 PCT/NZ2003/000278 NZ0300278W WO2005056801A1 WO 2005056801 A1 WO2005056801 A1 WO 2005056801A1 NZ 0300278 W NZ0300278 W NZ 0300278W WO 2005056801 A1 WO2005056801 A1 WO 2005056801A1
Authority
WO
WIPO (PCT)
Prior art keywords
altered
genetic
seq
protein
sequence
Prior art date
Application number
PCT/NZ2003/000278
Other languages
English (en)
Inventor
Matthew Glenn
Ilkka Havukkala
Mark William Lubbers
James Dekker
Original Assignee
Genesis Research And Development Corporation Limited
Fonterra Co-Operative Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Research And Development Corporation Limited, Fonterra Co-Operative Group Limited filed Critical Genesis Research And Development Corporation Limited
Priority to EP03781132A priority Critical patent/EP1711609A1/fr
Priority to AU2003288826A priority patent/AU2003288826A1/en
Priority to CA002549710A priority patent/CA2549710A1/fr
Priority to PCT/NZ2003/000278 priority patent/WO2005056801A1/fr
Publication of WO2005056801A1 publication Critical patent/WO2005056801A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention relates to polynucleotides isolated from lactic acid bacteria as well as to probes and primers specific to the polynucleotides; genetic constructs comprising the polynucleotides; biological materials, including plants, microorganisms and multicellular 10 organisms, incorporating the polynucleotides; polypeptides expressed by the polynucleotides; and methods for using the polynucleotides and polypeptides.
  • the present invention relates to polynucleotides isolated from a specific strain of lactic 15 acid bacteria, namely Lactobacillus rhamnosus HNOOl (L. rhamnosus HNOOl). Lactic acid bacteria, and their enzymes, are the major determinants of flavor and fermentation characteristics in fermented dairy products, such as cheese and yogurt. Flavors are produced through the action of bacteria and their enzymes on proteins, carbohydrates and lipids.
  • Lactobacillus rhamnosus strain HNOOl are heterofermentative bacteria that are Gram 20 positive, non-motile, non-spore fo ⁇ ning, catalase negative, facultative anaerobic rods exhibiting an optimal growth temperature of 37 ⁇ 1°C and an optimum pH of 6.0 - 6.5.
  • Experimental studies demonstrated that dietary supplementation with Lactobacillus rhamnosus strain HNOOl induced a sustained enhancement in several aspects of both natural and acquired immunity (See PCT International Publication No. WO 99/10476).
  • L. 25 rhamnosus HNOOl, and certain other Gram-positive bacteria can specifically and directly modulate human and animal health (See, for example, Tannock et al., Applied Environ.
  • Lactic Acid Bacteria, Salminen S and von Wright A (eds)., Marcel Dekker Inc, New York, Basel, Hong Kong, pp. 139-159; Isolauri et al., S 1998.
  • Lactic Acid Bacteria, Salminen S and von Wright A (eds)., Marcel Dekker Inc, New York, Basel, Hong Kong, pp. 255-268; Lichtenstein and Goldin, 1998.
  • Lactic Acid Bacteria, Sahninen S and von Wright A (eds)., Marcel Dekker Inc, New York, Basel, Hong Kong, pp. 269-277; El-Nezami and Ahokas, 1998.
  • Lactic Acid Bacteria, Salminen S and von Wright A (eds)., Marcel Dekker Inc, New York, Basel, Hong Kong, pp. 359-367; Mattianen et al, 1998.
  • Lactic Acid Bacteria, Salminen S and von Wright A (eds)., Marcel Dekker Inc, New York, Basel, Hong Kong, pp. 437-473; Meisel and Bockelmann, Antonie van Leeuwenhoek 76:207-215, 1999; Christensen et al, Antonie van Leeuwenhoek 76:217-246, 1999; Dunne et al, Antonie van Leeuwenhoek 76:279-292, 1999).
  • Beneficial health effects attributed to these bacteria include the following: Increased resistance to enteric pathogens and anti-infection activity, including treatment of rotavirus infection and infantile diarrhea - due to increases in antibody production caused by an adjuvant effect, increased resistance to pathogen colonization; alteration of intestinal conditions, such as pH; and the presence of specific antibacterial substances, such as bacteriocins and organic acids.
  • Anti-cancer in particular anti-colon cancer
  • anri-mutagenesis activities due to anti- mutagenic activity
  • alteration of procancerous enzymatic activity of colomc microbes reduction of the carcinogenic enzymes azoreductase, beta-glucuronidase and nitroreductase in the gut and/or faeces
  • stimulation of immune function positive influence on bile salt concentration; and antioxidant effects.
  • L. rhamnosus include: improved nutrition; regulation of colonocyte proliferation and differentiation; improved lignan and isoflavone metabolism; reduced mucosal permeability; detoxification of carcinogens and other harmful compounds; relief of constipation and diarrhea; and vitamin synthesis, in particular folate.
  • Peptidases are enzymes that break the peptide bonds linking the amino group of one amino acid with the carboxy group (acid group) of an adjacent amino acid in a peptide chain. The bonds are broken in a hydrolytic reaction.
  • exopeptidases include: • Aminopeptidases - release a free amino acid from the N-terminus of a peptide chain; • dipeptidyl-peptidase (also known as dipeptidyl-aminopeptidases) - release a dipeptide from the N-terminus of a peptide chain; • tripeptidyl-peptidases (also known as tripeptidyl-aminopeptidases) - release a tripeptide from the N-terminus of a peptide chain); • carboxypeptidases - release a free amino acid from the C-terminus of a peptide chain; • peptidyl-dipeptidase - release a dipeptide from the C-terminus of a peptide chain; • dipeptidases - release two free amino acids from a dipeptide; and • tripeptidases - release a free amino acid and a dipeptide from a tripeptide.
  • Peptidases are important enzymes in the process of cheese ripening and the development of cheese flavor.
  • the hydrolysis of milk caseins in cheese results in textural changes and the development of cheese flavors.
  • the raft of proteolytic enzymes that cause this hydrolysis come from the lactic acid bacteria that are bound up in the cheese - either starter cultures that grow up during the manufacture of the cheese, or adventitious and adjunct non-starter lactic acid bacteria that grow in the cheese as it ripens (Law Haandrikman, Int. Dairy J. 7:1-11, 1997).
  • Many other enzymes can also influence dairy product flavor, and functional and textural characteristics, as well as influencing the fermentation characteristics of the bacteria, such as speed of growth, acid production and survival (Urbach, Int. Dairy J.
  • Enzymes influencing specific characteristics and/or functions include the following: ⁇ Lysis of cells. These enzymes are mostly cell wall hydrolases, including amidases; muramidases; lysozymes, including N-acetyl muramidase; muramidase; N- acetylglucosaminidase; and N-acetylmuramoyl-L-alanine amidase. DEAD-box helicase proteins also influence autolysis.
  • Lactose, citrate and diacetyl metabolism, and alcohol metabolism are particularly important.
  • the enzymes involved include beta-galactosidase, lactate dehydrogenase, citrate lyase, citrate permease, 2,3 butanediol dehydrogenase (acetoin reductase), acetolactate decarboxylase, acetolactate synthase, pyruvate decarboxylase, pyruvate formate lyase, diacetyl synthase, diacetyl reductase, alcohol decarboxylase, lactate dehydrogenase, pyruvate dehydrogenase, and aldehyde dehydrogenase.
  • Enzymes involved include lipases, esterases, phospholipases, serine hydrolases, desaturases, and linoleate isomerase.
  • Polysaccharides are important not only for potential immune enhancement and adhesion activity but are important for the texture of fermented dairy products.
  • the enzymes involved are a series of glucosyl transferases, including beta-(l-3) glucosyl transferase, alpha-N acetylgalactosaminyl transferase, phosphogalactosyl transferase, alpha-glycosyl transferase, UDP-N-acetylglucosamine C4 epimerase and IJDP-N-acetylglucosamine transferase.
  • Enzymes include glutamate dehydrogenase, aminotransferases, amino acid decarboxylases, and enzymes involved in sulphur amino acid degradation including cystathione beta-lyase.
  • Polynucleotides identified using sequencing techniques may be partial or full-length genes, and may contain open reading frames, or portions of open reading frames, that encode polypeptides. Putative polypeptides may be identified based on polynucleotide sequences and further characterized. The sequencing data relating to polynucleotides thus represents valuable and useful information. Polynucleotides and polypeptides may be analyzed for varying degrees of novelty by comparing identified sequences to sequences published in various public domain databases, such as EMBL.
  • Newly identified polynucleotides and co ⁇ esponding putative polypeptides may also be compared to polynucleotides and polypeptides contained in public domain information to ascertain homology to known polynucleotides and polypeptides. In this way, the degree of similarity, identity or homology of polynucleotides and polypeptides having an unknown function may be determined relative to polynucleotides and polypeptides having known functions.
  • Information relating to the sequences of isolated polynucleotides may be used in a variety of ways. Specified polynucleotides having a particular sequence may be isolated, or synthesized, for use in in vivo or in vitro experimentation as probes or primers. Alternatively, collections of sequences of isolated polynucleotides may be stored using magnetic or optical storage medium and analyzed or manipulated using computer hardware and software, as well as other types of tools.
  • the present invention provides isolated polynucleotides comprising a sequence selected from the group consisting of: (a) sequences identified in the attached Sequence Listing as SEQ ID NOS: 1-80; (b) variants of those sequences; (c) extended sequences comprising the sequences set out in SEQ ID NOS: 1-80, and their variants; and (d) sequences comprising at least a specified number of contiguous residues of a sequence of SEQ ID NOS: 1-80 (x-mers). Oligonucleotide probes and primers co ⁇ esponding to the sequences set out in SEQ ED NOS: 1-80, and their variants are also provided.
  • polynucleotides of the present invention All of these polynucleotides and oligonucleotide probes and primers are collectively refe ⁇ ed to herein, as "polynucleotides of the present invention.”
  • the polynucleotide sequences identified as SEQ ID NOS: 1-80 were derived from a microbial source, namely from fragmented genomic DNA of Lactobacillus rhamnosus, strain HNOOl, described in PCT International Publication No. WO 99/10476.
  • Lactobacillus rhamnosus strain HNOOl are heterofermentative bacteria that are Gram positive, non-motile, non-spore for ⁇ iing, catalase negative, facultative anaerobic rods exhibiting an optimal growth temperature of 37+1 °C and an optimum pH of 6.0 - 6.5.
  • Experimental studies demonstrated that dietary supplementation with Lactobacillus rhamnosus strain HNOOl induced a sustained enhancement in several aspects of both natural and acquired immunity.
  • a biologically pure culture of Lactobacillus rhamnosus strain HNOOl was deposited at the Australian Government Analytical Laboratories (AGAL), The New South Wales Regional Laboratory, 1 Suakin Street, Pymble, NSW 2073, Australia, as Deposit No.
  • polynucleotide sequences disclosed herein are "partial" sequences in that they do not represent a full-length gene encoding a full-length polypeptide. Such, partial sequences may be extended by analyzing and sequencing various DNA libraries using primers and/or probes and well-known hybridization and/or PCR techniques. The partial sequences disclosed herein may thus be extended until an open reading frame encoding a polypeptide, a full-length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified.
  • Such extended sequences including full-length polynucleotides and genes, are described as "co ⁇ esponding to" a sequence identified as one of the sequences of SEQ ID NOS: 1-80 or a variant thereof, or a portion of one of the sequences of SEQ ID NOS: 1-80 or a variant thereof, when the extended polynucleotide comprises an identified sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1-80 or a variant thereof.
  • the polynucleotides identified as SEQ ID NOS: 1-80 were isolated from Lactobacillus rhamnosus genomic DNA clones and represent sequences that are present in the cells from which the DNA was prepared.
  • sequence information may be used to identify and isolate, or synthesize, DNA molecules such as promoters, DNA-binding elements, open reading frames or full-length genes, that then can be used as expressible or otherwise functional DNA in transgenic organisms.
  • DNA molecules such as promoters, DNA-binding elements, open reading frames or full-length genes
  • RNA sequences, reverse sequences, complementary sequences, antisense sequences and the like, co ⁇ esponding to the polynucleotides of the present invention may be routinely ascertained and obtained using the polynucleotides identified as SEQ ID NOS: 1-80.
  • the present invention further provides isolated polypeptides encoded, or partially encoded, by the polynucleotides disclosed herein.
  • polypeptides of the present invention comprise a sequence selected from the group consisting of sequences identified as SEQ ED NO: 81-183, and variants thereof.
  • Polypeptides encoded by the polynucleotides of the present invention may be expressed and used in various assays to determine their biological activity. Such polypeptides may be used to raise antibodies, to isolate co ⁇ esponding interacting proteins or other compounds, and to quantitatively detern ine levels of interacting proteins or other compounds.
  • Genetic constructs comprising the inventive polynucleotides are also provided, together with transgenic host cells comprising such constructs and transgenic organisms, such as microbes, comprising such cells.
  • the present invention also contemplates methods for modulating the polynucleotide and/or polypeptide content and composition of an organism, such methods involving stably incorporating into the genome of the organism a genetic construct comprising a polynucleotide of the present invention.
  • the target organism is a microbe, preferably a microbe used in fermentation, more preferably a microbe of the genus Lactobacillus, and most preferably Lactobacillus rhamnosus, or other closely microbial related species used in the . dairy industry.
  • methods for producing a microbe having an altered genotype and/or phenotype comprising fransfo ⁇ ning a microbial cell with a genetic construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to growth and multiplication.
  • Organisms having an altered genotype or phenotype as a result of modulation of the level or content of a polynucleotide or polypeptide of the present invention compared to a wild-type organism, as well as components and progeny of such organisms, are contemplated by and encompassed within the present invention.
  • the isolated polynucleotides of the present invention may be usefully employed for the detection of lactic acid bacteria, preferably L.
  • inventive polynucleotides and polypeptides may also be employed in methods for the selection and production of more effective probiotic bacteria; as "bioactive" (health- promoting) ingredients and health supplements for immune function enhancement; for reduction of blood lipids such as cholesterol; for production of bioactive material from genetically modified bacteria; as adjuvants; for wound healing; in vaccine development, particularly mucosal vaccines; as animal probiotics for improved animal health and productivity; in selection and production of genetically modified rumen microorganisms for improved animal nutrition and productivity, better flavor and improved milk composition; in methods for the selection and production of better natural food bacteria for improved flavor, faster flavor development, better fermentation characteristics, vitamin synthesis and improved textural characteristics; for the production of improved food bacteria through genetic modification; and for the identification of novel enzymes for the production of, for example, flavors or aroma concentrates.
  • the isolated polynucleotides of the present invention also have utility in genome mapping, in physical mapping, and in positional cloning of genes of more or less related microbes. Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-80, and their variants, may be used to design oligonucleotide probes and primers. Such oligonucleotide probes and primers have sequences that are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide.
  • Oligonucleotide probes designed using the polynucleotides of the present invention may be used to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA sequences in their cells, using techniques that are well known in the art, such as slot blot DNA hybridization techniques.
  • Oligonucleotide primers designed using the polynucleotides of the present invention may be used for polymerase chain reaction (PCR) amplifications.
  • PCR polymerase chain reaction
  • Ohgonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with various microa ⁇ ay technologies, including the microarray technology of Affymetrix (Santa Clara, CA).
  • the polynucleotides of the present invention may also be used to tag or identify an organism or derived material or product therefrom. Such tagging may be accomplished, for example, by stably introducing a non-disruptive non-functional heterologous polynucleotide identifier into an organism, the polynucleotide comprising at least a portion of a polynucleotide of the present invention.
  • the polynucleotides of the present invention may also be used as promoters, gene regulators, origins of DNA replication, secretion signals, cell wall or membrane anchors for genetic tools (such as expression or integration vectors). All references cited herein, including patent references and non-patent publications, are hereby incorporated by reference in their entireties.
  • Fig. 1 shows the nucleotide sequence for L. rhamnosus strain HNOOl deoD purine nucleoside phosphorylase g/. (SEQ ID NO: 78), showing ATG initiation and translation stop codons (boxed).
  • Fig. 2 shows the amino acid sequence for L. rhamnosus strain HNOOl deoD purine nucleoside phosphorylase ⁇ / (SEQ ID NO: 181).
  • Fig. 3 shows the results of UV light exposure assay measuring relative viability in response to increasing doses of UV light fo ⁇ AQF HNOOl strain ( ⁇ ) and wild-type HNOOl ( ⁇ ).
  • Fig. 4 shows the nucleotide sequence for L. rhamnosus strain HNOOl relA GTP pyrophosphokinase gene AMI (SEQ ID NO: 79) showing ATG initiation and translation stop codons (boxed).
  • Fig. 5 shows the amino acid sequence of L. rhamnosus strain HNOOl relA GTP pyrophosphokinase gene ⁇ MZ (SEQ H) NO: 182).
  • Example 6 shows the results of UV light exposure assay measuring relative viability in response to increasing doses of UV light in AMI ' HNOOl strain ( ⁇ ) and wild-type HNOOl ( ⁇ ). Results indicate that the AMI ' HNOOl mutant strain showed enhanced survival to exposure to UV light compared to wild-type HNOOl .
  • the polynucleotides disclosed herein were isolated by high throughput sequencing of DNA libraries from the lactic acid bacteria Lactobacillus rhamnosus as described below in Example 1.
  • Cell wall, cell surface and secreted components of lactic acid bacteria are known to mediate immune modulation, cell adhesion and antibacterial activities, resulting in many beneficial effects including: resistance to enteric pathogens; modulation of cancer, including colon cancer; anti-mutagenesis effects; reduction of small bowel bacterial overgrowth; modulation of auto-immune disorders; reduction in allergic disorders; modulation of urogenital infections, inflammatory bowel disorder, irritable bowel syndrome, Helicobacter pylori infection and hepatic encephalopathy; reduction of infection with pathogens; regulation of colonocyte proliferation and differentiation; reduction of mucosal permeability; and relief of constipation and diarrhea
  • These cell components include, but are not limited to, peptidoglycans, teichoic acids, lipoteichoic acids, polysaccharides, adhesion proteins, secreted proteins, surface layer or S-layer proteins, collagen binding proteins and other cell surface proteins, and antibacterial substances such as bacteriocins and organic acids produced by
  • Polynucleotides involved in the synthesis of these proteins and in the synthesis, modification, regulation, transport, synthesis and/or accumulation of precursor molecules for these proteins can be used to modulate the immune effects, antibacterial, cell adhesion and competitive exclusion effects of the bacteria or of components that might be produced by these bacteria.
  • L. rhamnosus HNOOl In order to function effectively as probiotic bacteria, L. rhamnosus HNOOl must survive environmental stress conditions in the gastrointestinal tract, as well as commercial and industrial processes.
  • Polynucleotides involved in stress resistance often confer multistress resistance, i.e., when exposed to one stress, surviving cells are resistant to several non-related stresses.
  • Bacterial genes and/or processes shown to be involved in multistress resistance include:
  • Osmoregulatory molecules - small choline-based molecules such as glycine-betaine, and sugars, such as trehalose, are protective against osmotic shock and are rapidly imported and/or synthesized in response to increasing osmolarity.
  • Stress response genes a number of genes appear to be induced or repressed by heat shock, cold shock, and increasing salt through the action of specific promoters.
  • the isolated polynucleotides of the present invention may be employed to produce bacteria having desired phenotypes, including increased resistance to stress and improved fermentation properties.
  • Many enzymes are known to influence dairy product flavor, functional and textural characteristics as well as general fermentation characteristics such as speed of growth, acid production and survival. These enzymes include those involved in the metabolism of lipids, polysaccharides, amino acids and carbohydrates as well as those involved in the lysis of the bacterial cells.
  • the isolated polynucleotides and polypeptides of the present invention have demonstrated similarity to polynucleotides and/or polypeptides of known function. The identity and functions of the inventive polynucleotides based on such similarities are shown below in Table 1. TABLE 1
  • LacG is part of the lactose Modified flavor, aroma, or metabolism, and hydrolyzes texture attributes.
  • phospholactose the product of a Construction of genetic vectors phosphor-enolpyruvate-dependent for controlled expression of RNA phosphotransferase system. It belongs and/or protein, fusion protein to the glycosidase family 1 and production, genetic modification, contributes to flavor, including bitter mutagenesis amplification of flavor. genetic material or for other genetic or protein manipulations.
  • Altered survival characteristics (survival of industrial processes, growth or storage in product formats, persistence in gut environment). Modified carbohydrate levels or functional properties. Altered metabolic properties. Modified lactose metabolism. Altered probiotic attributes. Improved fermentation properties or other industrially useful processes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health, lactose tolerance) 82 Production of bioactive or Homologue of pepS, encoding an functional polypeptides. aminopeptidase (EC 3.4.11.-). PepS Removal of undesirable flavor catalyzes the release of free amino characteristics. acids from peptides. Production of desirable flavors.
  • Aminopeptidases are exopeptidases Modified flavor, aroma and/or and ubiquitous enzymes, frequentiy texture attributes. observed in animals, plants and Construction of genetic vectors microorganisms. They are involved in for controlled expression of RNA many different functions in the cell, and/or protein, fusion protein such as protein maturation, protein production, genetic modification, turnover, hydrolysis of regulatory mutagenesis amplification of peptides, nitrogen nutrition, genetic material or for other modulation of gene expression etc.
  • SEQ SEQ LD SEQ SEQ LD
  • the proteolytic survival of industrial processes, system of lactic acid bacteria is growth or storage in product essential for bacterial growth in milk formats, persistence in gut but also for the development of the environment. organoleptic properties of dairy Altered metabolic properties or products.
  • PepS is involved both in regulation of metabolic bacterial growth by supplying amino pathways. acids, and in the development of Altered probiotic attributes. flavor in dairy products, by Organisms or materials with hydrolyzing peptides (including bitter improved health properties peptides) and liberating aromatic (including immunoregulatory, amino acids which are important anticancer, gut health). precursors of aroma compounds Altered resistance to antibiotics.
  • PepC and/or protein, fusion protein belongs to peptidase family CI; also production, genetic modification, known as the papain family of thiol mutagenesis amplification of proteases and is involved in flavor genetic material or for other production.
  • the proteolytic system of genetic or protein manipulations, lactic acid bacteria is essential for Altered survival characteristics: bacterial growth in milk but also for survival of industrial processes, the development of the organoleptic growth or storage in product properties of dairy products. formats, persistence in gut environment. Altered metabolic properties or regulation of metabolic pathways. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health). Altered resistance to antibiotics. 84 [Altered amino acid metabolism.
  • the biosynthesis of histidine production, genetic modification, is a central metabolic process in mutagenesis amplification of organisms ranging from bacteria to genetic material or for other yeast and plants. genetic or protein manipulations.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes.
  • Modified health properties including immunoregulatory, anticancer, gut health).
  • Modified antibiotic resistance Improved fermentation properties or other industrially useful processes.
  • MvaD Construction of genetic vectors is part of the mevalonate pathway for for controlled expression of RNAlthe biosynthesis of the central and/or protein, fusion protein isoprenoid precursor, isopentenyl production, genetic modification, diphosphate by catalyzing the mutagenesis amplification of reaction of mevalonate 5-diphosphate genetic material or for other with ATP to produce inorganic genetic or protein manipulations.
  • DNA Polypeptide improved health properties including immunoregulatory, anticancer, gut health). 86 Production of desirable flavors.
  • protein is a major extracellular Construction of genetic vectors product secreted by all isolates of L. for controlled expression of RNA monocytogenes. This protein has and/or protein, fusion protein peptidoglycan hydrolase activity but production, genetic modification, also influences the uptake of L. mutagenesis amplification of monocytogenes by non-phagocytic genetic material or for other cells. Proteins related to p60 are also genetic or protein manipulations, found in all other Listeria species.
  • p60 protein is survival of industrial processes, among the strongest antigens in growth or storage in product listeriae for B- and T-cell responses. formats, persistence in gut
  • the protein p60 belongs to the E. coli environment. pipe / listeria p60 family.
  • Altered metabolic properties Altered probiotic attributes. Modified adhesion to human or animal cells or cell lines. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health) Altered resistance to antibiotics. Improved antimicrobial properties.
  • RNA and 1 alpha (EF-1 alpha) that and/or protein, fusion protein are homologous proteins essential to production, genetic modification, translation in bacteria and eukaryotes, mutagenesis amplification of respectively.
  • EF-Tu and EF-1 alpha genetic material or for other are GTPases that catalyze the binding genetic or protein manipulations. of aminoacyl-tRNAs to the A-site of Production of desirable flavors. the ribosome. As they are among the Modified flavor, aroma and/or slowest evolving proteins known, EFs texture attributes.
  • RNAse HII The prokaryotic RNAse HII is the survival of industrial processes, evolutionary counterpart of the major growth or storage in product mammalian RNase rl (Frank et al, formats, persistence in gut Proc. Natl. Acad. Sci. USA 95: 12872- environment. 12877, 1998) and is necessary for cell Altered metabolic properties or survival. regulation of metabolic pathways. Altered probiotic attributes. 10 90 Production of desirable flavors. Lipase homologue. Lipases are Modified flavor, aroma and/or enzymes that catalyze hydrolysis of texture attributes. fatty acid ester bonds in Construction of genetic vectors triacylglycerol (TAG) and releasing for controlled expression of RNA free fatty acids.
  • TAG triacylglycerol
  • the reaction is and/or protein, fusion protein reversible and therefore the enzyme production, genetic modification, can catalyze esterif ⁇ cation of glycerol mutagenesis amplification of to form mono, di and triglycerides.
  • genetic material or for other Free fatty acids are important in genetic or protein manipulations.
  • Altered survival characteristics for dairy products such as cheese, and survival of industrial processes, have a significant role in both flavor growth or storage in product and texture. Used extensively in wide formats, persistence in gut range of convenience foods. Short environment. chain fatty acids are known to have a Altered metabolic properties. variety of health impacts. Modified lipid, glycolipid or free fatty acid levels or functional properties. Modified production of short chain fatty acids. Altered lipid metabolism. Altered probiotic attributes. SEQ SEQ ID
  • ⁇ D O NO Utility Description DNA Polypeptide Organisms or materials with improved health properties (including irnmunoregulatory, anticancer, gut health). 11 91 Altered amino acid metabolism. Homologue of hisD, encoding Removal of undesirable flavor histidinol dehydrogenase (HDH, EC characteristics. 1.1.1.23). HisD catalyzes the last two Production of desirable flavors. steps in the biosynthesis of L- Modified flavor, aroma and/or histidine: sequential NAD-dependent texture attributes. oxidations of L-histidinol to L- Construction of genetic vectors histidinaldehyde and then to L- for controlled expression of RNA histidine.
  • HDH undesirable flavor histidinol dehydrogenase
  • hisD is absent in and/or protein, fusion protein mammals, it is a target for inhibition production, genetic modification, as part of herbicide development mutagenesis amplification of (Barbosa et al, Proc. Natl. Acad. Sci. genetic material or for other USA 99:1859-1864, 2002) genetic or protein manipulations
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. 11 92 Altered amino acid metabolism Homologue of hisZ, coding for an Removal of undesirable flavor aminoacyl-tRNA synthetase. HisZ is characteristics.
  • HisG histidine biosynthesis with Modified flavor, aroma and/or ATP phosphoribosyltransferase texture attributes.
  • HisZ is also for controlled expression of RNA called an ATP and or protein, fusion protein phosphoribosyltransferase regulatory production, genetic modification, subunit. HisZ is required for histidine mutagenesis amplification of prototrophy and directly involved in genetic material or for other the transferase function. Both HisG genetic or protein manipulations. and HisZ are required for catalyzing Altered survival characteristics: the ATP phosphoribosyltransferase survival of industrial processes, reaction. Aminoacyl-tRNA growth or storage in product synthetases have an essential catalytic formats, persistence in gut role in protein biosynthesis, but also 5/056801
  • PlnG displays strong similarities and/or protein, fusion protein to the proposed transport proteins of production, genetic modification, several other bacteriocins and to mutagenesis amplification of proteins implicated in the signal- genetic material or for other sequence-independent export of genetic or protein manipulations.
  • Escherichia coli hemolysin, PlnH is Altered survival characteristics: its accessory protein (Huhne et al, survival of industrial processes, Microbiol. 142:1437-1448, 1996). growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer gut health). Modified antibiotic resistance. Improved antimicrobial properties.
  • Altered survival characteristics specific apoproteins, it serves a wide survival of industrial processes, range of important functions growth or storage in product including electron transport (e.g., formats, persistence in gut cytochromes), binding and transport environment. of 0 2 (e.g., hemoglobin), and Altered metabolic properties or oxidative catalysis (e.g., peroxidases) regulation of metabolic (Fischer et al, J. Bacteriol. pathways. 183:1300-1311, 2001). Altered probiotic attributes. Altered antimicrobial properties. Modified health properties (including immunoregulatory, anticancer gut health). SEQ SEQ ID NO NO: Utility Description
  • LacD is responsible attributes. for the aldol cleavage of tagatose-1,6- Construction of genetic vectors bisphosphate to form glycerone-P and for controlled expression of RNA glyceraldehyde 3 -phosphate in the and/or protein, fusion protein tagatose 6-phosphate pathway of production, genetic modification, lactose catabolism in bacteria.
  • the mutagenesis amplification of enzyme activity is stimulated by genetic material or for other certain divalent cations. genetic or protein manipulations.
  • Altered survival characteristics (survival of industrial processes, growth or storage in product formats, persistence in gut environment). Modified carbohydrate levels or functional properties. Altered metabolic properties. Modified lactose metabolism. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health, lactose tolerance).
  • DNA Polypeptide formats persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes. 19 101 Removal of undesirable flavor Homologue of butB, encoding 2,3- characteristics. butanediol dehydrogenase (EC Production of desirable flavors. 1.1.1.4). ButB catalyzes the NAD+- Modified flavor, aroma and/or dependent oxidation of 2,3- texture attributes. butanediol acetoin, as well as the Construction of genetic vectors co ⁇ esponding reverse reactions. It for controlled expression of RNA can also reduce diacetyl to acetoin.
  • Diacetyl is an important flavor production, genetic modification, compound in dairy products. mutagenesis amplification of genetic material or for other genetic or protein manipulations.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes. 0 102 Altered cell wall or cell surface Homologue of a peptidoglycan characteristics, structures or hydrolase (N-acetylmuramoyl-L- functions. anine amidase).
  • N-acetylmuramoyl- Modified adhesion to human or L-alanine amidase is an autolysin animal cells or cell lines. involved in degrading the cell wall Production of desirable flavors. during cell growth or programmed Modified flavor, aroma and or cell death and is involved in cell texture attributes. growth and important for releasing Construction of genetic vectors enzymes important for flavor. l SEQ SEQ ED NO NO: Utility Description
  • DNA Polypeptide for controlled expression of RNA and/or protein, fusion protein production, genetic modification, mutagenesis amplification of genetic material or for other genetic or protein manipulations Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes.1, 76 103, 175 Altered cell wall or cell surface Homologue of galC, encoding characteristics, structures or galactosylceramidase (EC 3.2.1.46). functions.
  • GalC hydrolyzes galactose ester Modified adhesion to human or bonds of galactosylceramide, animal cells or cell lines. galactosylsphingosine, Production of desirable flavors. monogalactosyldiglyceride and Modified flavor, aroma and or lactosylceramide. It is involved in texture attributes. the catabolism of galactosylceramide, Construction of genetic vectors a major lipid in myelin, kidney and for controlled expression of RNA epithelial cells of small intestine and and/or protein, fusion protein colon.
  • bacteria may use galC production, genetic modification, to release sugars for metabolism, the mutagenesis amplification of by-products, including ceramide, asct genetic material or for other as signalling molecules in eukaryotic genetic or protein manipulations. cells and can lead to apoptosis or Altered survival characteristics: differentiation. Therefore, glaC plays survival of industrial processes, a role in probiotic effects and survival growth or storage in product in the gut environment. formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health, apoptosis). Modified antibiotic resistance. SEQ SEQ ⁇ D
  • DNA Polypeptide Improved antimicrobial properties. Improved fermentation properties or other industrially useful processes. 22 104 Production of bioactive or Homologue of pepN, encoding functional polypeptides. membrane alanyl aminopeptidase Removal of undesirable flavor (EC 3.4.11.2), also called lysyl characteristics. aminopeptidase and aminopeptidase Production of desirable flavors. N. PepN releases the N-terminal Modified flavor, aroma and/or amino acid, Xaa-
  • Aminopeptidases are involved in for controlled expression of RNA many different functions in the cell, and/or protein, fusion protein such as protein maturation, protein production, genetic modification, turnover, hydrolysis of regulatory mutagenesis amplification of peptides, nitrogen nutrition, genetic material or for other modulation of gene expression etc. genetic or protein manipulations. and, consequentiy, are considered Altered survival characteristics: essential enzymes.
  • the proteolytic survival of industrial processes, system of lactic acid bacteria is growth or storage in product essential for bacterial growth in milk formats, persistence in gut but also for the development of the environment. organoleptic properties of dairy Altered metabolic properties or products. PepN is involved both in regulation of metabolic bacterial growth by supplying amino pathways. acids, and in the development of Altered probiotic attributes.
  • MvaB catalyzes the Construction of genetic vectors condensation of acetyl-CoA with for controlled expression of RNA acetoacetyl-CoA to form 3-hydroxy- and/or protein, fusion protein 3-methylglutaryl-CoA and CoA. production, genetic modification, MvaB is involved in mevalonic acid mutagenesis amplification of metabolism as well as in biosynthesis genetic material or for other of cholesterol and ubiquinone genetic or protein manipulations, progenitors. Terpenoids or Altered survival characteristics: [isoprenoids constifate a vast family of SEQ SEQ ID
  • PMS1 gene product which is likely Altered metabolic properties or to be involved in a mismatch regulation of metabolic co ⁇ ection system in Saccharomyces pathways. cerevisiae (Prud Subscribe et al, J. Altered probiotic attributes. Bacteriol. 171 :5332-5338, 1989). 25 107 Altered amino acid metabolism. Homologue of araT, encoding an Removal of undesirable flavor aromatic amino acid aminotransferase characteristics. (EC 2.6.1.57). Aminotransferases Production of desirable flavors. have been widely applied in the Modified flavor, aroma and/or large-scale biosynthesis of amino texture attributes. acids, which are in increasing Construction of genetic vectors demand by the pharmaceutical for controlled expression of RNA industry.
  • AraT plays a major role in and/or protein, fusion protein the conversion of aromatic amino production, genetic modification, acids to aroma compounds. AraT also mutagenesis amplification of has a major physiological role in the genetic material or for other biosynthesis of phenylalanine and /056801
  • HD NO NO Utility Description DNA Polypeptide genetic or protein manipulations tyrosine.
  • TagE Altered cell wall or cell surface Homologue of tagE, encoding characteristics, structures or poly(glycerol-phosphate) alpha- functions.
  • glucosyltransferase (EC 2.4.1.52) Modified adhesion to human or also called uridine diphosphate- animal cells or cell lines. glucose poly-(glycerol phosphate) Production of desirable flavors. alpha-glucosyl transferase.
  • TagE is Modified flavor, aroma and/or involved in techoic acid synthesis. texture attributes.
  • Techoic acid is one component of the Construction of genetic vectors thick peptidoglycan layers in the cell for controlled expression of RNA wall of Gram-positive bacteria and is and/or protein, fusion protein susceptible to the enzyme lysozyme production, genetic modification, and to penicillin, mutagenesis amplification of genetic material or for other genetic or protein manipulations
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties. Altered probiotic attributes. Modified health properties (mcluding immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes.
  • HD NO NO Utility Description DNA Polypeptide Removal of undesirable flavor histidine biosynthesis bifunctional characteristics.
  • HisB rea anges the Construction of genetic vectors imidazole glycerol phosphate by a for controlled expression of RNA redox-neutral dehydrative reaction to and/or protein, fusion protein imidazole acetol phosphate and production, genetic modification, catalyzes the dephosphorylation of mutagenesis amplification of hisidinol phosphate to histidinol, the genetic material or for other direct precursor of histidine. Because genetic or protein manipulations. hisB is absent from mammals, it has Altered survival characteristics: become a target for inhibition as part survival of industrial processes, of herbicide development (Barbosa et growth or storage in product al, Proc. Natl. Acad. Sci.
  • CysK catalyzes Modified flavor, aroma and/or the formation of L-cysteine, the last texture attributes.
  • step of L-cysteine biosynthesis from Construction of genetic vectors 0-acetyl-L-serine and hydrogen for controlled expression of RNA sulfide.
  • Cysteine synthase is involved and/or protein, fusion protein in the assimilatory sulfate reduction production, genetic modification, pathway and in the selenium mutagenesis amplification of incorporation into proteins, which genetic material or for other occurs mainly as selenocysteine, in genetic or protein manipulations.
  • bacteria Sulphur-containing amino Altered survival characteristics: acid metabolism is important for survival of industrial processes, development of aroma and flavor growth or storage in product compounds. formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health).
  • SEQ SEQ ED Modified health properties (including immunoregulatory, anticancer, gut health
  • Enn has characteristics, structures or unique Ig-binding characteristics as it functions. reacts preferentially with human Modified adhesion to human or gG3, the tlpC gene. Enn is a animal cells or cell lines. membrane protein with similarity to Production of desirable flavors. methyl-accepting chemotaxis proteins Modified flavor, aroma and/or and the streptococcal M proteins texture attributes. homologous with immunoglobulin- Construction of genetic vectors binding factors. The M proteins have for controlled expression of RNA been studied because of their and/or protein, fusion protein antiphagocytic function.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. 30 112 Altered amino acid metabolism. Homologue of hisE, encoding a Removal of undesirable flavor histidine biosynthesis protein that characteristics. plays a role in histidine biosynthesis. Production of desirable flavors. Because hisE is absent in mammals, Modified flavor, aroma and/or it is a target for inhibition as part of texture attributes. herbicide development (Barbosa et Construction of genetic vectors al, Proc. Natl.
  • RNA 99:1859-1864, 2002 Amino acid and/or protein, fusion protein degradation products in various production, genetic modification, cheeses have been shown to greatly mutagenesis amplification of contribute to flavor or to off-flavors genetic material or for other (Rijnen et al, Appl. Environ. genetic or protein manipulations. Microbiol. 65:4873-4880, 1999).
  • Altered survival characteristics survival of industrial processes, growth or storage in product SEQ SEQ ED ⁇ D NO: NO: Utility Description DNA Polypeptide formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance.
  • DNA Polypeptide formats persistence in gut environment. Altered metabolic properties. Modified lipid, glycolipid or free fatty acid levels or functional properties. Modified production of short chain fatty acids. Altered lipid metabohsm. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health). 32 115 AAlltteerreedd aammiinnoo aacciidd mmeettaabboolliissmm.. Homologue of glnA that encodes a Removal of undesirable flavor glutamine synthetase (EC 6.3.1.2), characteristics. also called glutamate-ammonia Production of desirable flavors. ligase.
  • GlnA catalyzes the first step in Modified flavor, aroma and/or the conversion of inorganic nitrogen texture attributes. (ammonium) into its organic form Construction of genetic vectors glutamine (Gin).
  • Bacterial glutamine for controlled expression of RNA synthetase export is associated with and/or protein, fusion protein pathogenicity and with the formation production, genetic modification, of a poly-L-glutamate/glutamine cell mutagenesis amplification of wall structure.
  • Glutamine synthetase genetic material or for other is an enzyme that plays a central role genetic or protein manipulations. in the nitrogen metabohsm.
  • the Altered survival characteristics enzyme and its products have roles in survival of industrial processes, flavor and growth. growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Altered cell wall or cell surface characteristics, structures or functions. 2 116 Altered cell wall or cell surface Homologue of Lipopolysaccharide characteristics, structures or synthesis protein yohJ. YohJ is functions. involved in techoic acid synthesis and Modified adhesion to human or important for cell wall functions animal cells or cell lines. including adhesion, immune cell SEQ SEQ IDj i D NO NO: Utility Description DNA Polypeptide Production of desirable flavors. interaction and product texture. Modified flavor, aroma and/or texture attributes.
  • RNA and/or protein Construction of genetic vectors for controlled expression of RNA and/or protein, fusion protein production, genetic modification, mutagenesis amplification of genetic material or for other genetic or protein manipulations.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. 33 117 Production of desirable flavors. Homologue of sorA. SorA encodes Modified flavor, aroma and/or the first protein of the texture attributes.
  • PTS RNA system
  • the ketose L-sorbose and/or protein, fusion protein is transported and phosphorylated production, genetic modification, through PTS.
  • the enzyme is useful in mutagenesis amplification of carbohydrate-specific regulation of genetic material or for other gene expression and flavor genetic or protein manipulations.
  • development Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Modified carbohydrate levels or functional properties. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health).
  • Homologue of sorF encoding D- Modified flavor, aroma and/or sorbitol-6-phosphate dehydrogenase, texture attributes.
  • the ketose L-sorbose is for controlled expression of RNA transported and phosphorylated and/or protein, fusion protein through the phosphoenolpyruvate- production, genetic modification, dependent L-sorbose-specific mutagenesis amplification of phosphotransferase system (PTS). genetic material or for other Useful for carbohydrate-specific genetic or protein manipulations. regulation of gene expression (Yebra Altered survival characteristics: et al., J. Bacteriol. 182:155-163, survival of industrial processes, 2000).
  • RNA A-minopeptidases are involved in and/or protein, fusion protein many different functions in the cell, production, genetic modification, such as protein maturation, protein mutagenesis amplification of turnover, hydrolysis of regulatory genetic material or for other peptides, nitrogen nutrition, genetic or protein manipulations. modulation of gene expression etc.
  • Altered survival characteristics and, consequently, are considered survival of industrial processes, essential enzymes.
  • the proteolytic growth or storage in product system of lactic acid bacteria is formats, persistence in gut essential for bacterial growth in milk environment. but also for the development of the Altered metabolic properties or organoleptic properties of dairy regulation of metabolic products. PepA is involved both in pathways. bacterial growth by supplying amino SEQ SEQ ED
  • Threonine is Modified flavor, aroma and/or derived from aspartic acid. texture attributes. Conversion of aspartate to Construction of genetic vectors homoserine proceeds with ATP for controlled expression of RNA activation of the B-carboxyl group as and/or protein, fusion protein a mixed phosphoric anhydride production, genetic modification, followed by two sequential NADPH- mutagenesis amplification of dependent reductions to homoserine genetic material or for other Phosphorylation of homoserine genetic or protein manipulations. provides the substrate Altered survival characteristics: phosphohomoserine which suffers a survival of industrial processes, stereospecific 1 ,2-transposition growth or storage in product reaction to give threonine. The formats, persistence in gut enzymatic degradation of amino acids environment.
  • Flotillins also known as epidermal for controlled expression of RNA surface antigens (ESAs)
  • ESAs RNA surface antigens
  • This enzyme enables Construction of genetic vectors bacteria to grow on a range of esters for controlled expression of RNA of aromatic alcohols and plays a role and/or protein, fusion protein in flavor development. production, genetic modification, mutagenesis amplification of genetic material or for other genetic or protein manipulations.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes.
  • Hsp 18 is induced not mutagenesis amplification of only by heat shock but also at the genetic material or for other onset of solventogenesis. Small heat genetic or protein manipulations. shock proteins (sHsps) are a diverse Production of desirable flavors. group of heat-induced proteins that Modified flavor, aroma and/or are conserved in prokaryotes and texture attributes. eukaryotes and are especially Altered survival characteristics: abundant in plants.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. 40 126 Production of desirable flavors. Homologue of sorE, encoding an L- Modified flavor, aroma and/or sorbose-1 -phosphate reductase. SorF texture attributes. is, together with D-glucitol-6- Construction of genetic vectors phosphate dehydrogenase, involved for controlled expression of RNA in the conversion of L-sorbose- 1- and/or protein, fusion protein phosphate to D-fructose-6-phosphate.
  • DNA Polypeptide improved health properties including immunoregulatory, anticancer, gut health). 41 127 Production of desirable flavors. Homologue of the iolB gene, Modified flavor, aroma and/or encoding a cis-acting catabolite- texture attributes. responsive element (ere) protein Construction of genetic vectors involved in the iol operon of the myo for controlled expression of RNA inositol catabolism pathway. Myo- and/or protein, fusion protein inositol is abundant in nature, production, genetic modification, especially in soil. Various mutagenesis amplification of microorganisms are able to grow on genetic material or for other myo-inositol as the sole carbon genetic or protein manipulations.
  • IolC Construction of genetic vectors phosphorylates the 2-deoxy-5-keto- for controlled expression of RNA D-gluconic acid to 2-deoxy-5-keto-D and/or protein, fusion protein gluconic acid 6-phosphate and is part production, genetic modification, of the iol operon of the myo-inositol mutagenesis amplification of catabolism pathway (Yoshida et al, genetic material or for other J. Bacteriol. 179:4591-4598, 1997). genetic or protein manipulations.
  • Myo-inositol is abundant in nature, Altered survival characteristics: especially in soil. Various survival of industrial processes, microorganisms are able to grow on growth or storage in product myo-inositol as the sole carbon formats, persistence in gut source.
  • Myo-inositol is for controlled expression of RNA abundant in nature, especially in soil. and/or protein, fusion protein
  • RNA abundant in nature especially in soil. and/or protein, fusion protein
  • Various microorganisms are able to production, genetic modification, grow on myo-inositol as the sole mutagenesis amplification of carbon source.
  • the expression of the genetic material or for other iol operon is under glucose repression genetic or protein manipulations. (Miwa and Fujita, J. Bacteriol. Altered survival characteristics: 183:5877-5884, 2001). survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Modified carbohydrate levels or functional properties. Altered cell wall or cell surface characteristics, structures or functions. Modified adhesion to human or animal cells or cell lines. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health).
  • IolG catalyzes the first SEQ SEQ ED H NO NO: Utility Description DNA Polypeptide Construction of genetic vectors reaction of the inositol catabolism, for controlled expression of RNAithe dehydrogenation of myo-inositol and/or protein, fusion protein onto 2-keto-myo-inositol (2-inosose) production, genetic modification, (Yoshida et al, J. Bacteriol. mutagenesis amplification of 179:4591-4598, 1997).
  • IolG is part of genetic material or for other the iol operon of the myo-inositol genetic or protein manipulations. catabolism pathway.
  • Myo-inositol is Altered survival characteristics: abundant in nature, especially in soil survival of industrial processes, Various microorganisms are able to growth or storage in product grow on myo-inositol as the sole formats, persistence in gut carbon source. The expression of the environment. iol operon is under glucose repression Altered metabolic properties. (Miwa and Fujita, J. Bacteriol. Modified carbohydrate levels or 183:5877-5884, 2001). functional properties. Altered cell wall or cell surface characteristics, structures or functions. Modified adhesion to human or animal cells or cell lines.
  • Organisms or materials with improved health properties including immunoregulatory, anticancer, gut health). 41 131 Production of desirable flavors.
  • Homologue of the iolJ gene Modified flavor, aroma and/or encoding fructose-bisphosphate texture attributes.
  • IolJ for controlled expression of RNA cleaves 2-deoxy-5-keto-D-gluconic and/or protein, fusion protein acid 6-phosphate to yield production, genetic modification, dihydroxyacetone phosphate and mutagenesis amplification of malonic semialdehyde and is part of genetic material or for other the iol operon of the myo-inositol genetic or protein manipulations.
  • catabolism pathway Yoshida et al, Altered survival characteristics: J. Bacteriol. 179:4591-4598, 1997). survival of industrial processes, Myo-inositol is abundant in nature, growth or storage in product especially in soil. Various formats, persistence in gut microorganisms are able to grow on environment.
  • RNA Myo-Inositol is abundant in nature, and/or protein, fusion protein especially in soil.
  • Various production, genetic modification microorganisms are able to grow on mutagenesis amplification of myo-inositol as the sole carbon genetic material or for other source.
  • the expression of the iol genetic or protein manipulations, operon is under glucose repression Altered survival characteristics: (Miwa and Fujita, J. Bacteriol. survival of industrial processes, 183:5877-5884, 2001).
  • the enzyme growth or storage in product is also required for growth on valine formats, persistence in gut and isoleucine as it is an acylating environment.
  • hisF Homologue of hisF, encoding Removal of undesirable flavor imidazole glycerol phosphate characteristics.
  • synthase subunit hisF (EC 4.1.3.-) Production of desirable flavors. also called IGP synthase cyclase Modified flavor, aroma and/or subunit.
  • HisF links histidine and de texture attributes. novo purine biosynthesis and is a Construction of genetic vectors member of the glutamine 056801
  • DNA Polypeptide for controlled expression of RNA amidotransferase family. and/or protein, fusion protein The enzymatic degradation of amino production, genetic modification, acids in cheese plays a major role in mutagenesis amplification of cheese flavor development.
  • Ainino genetic material or for other acid degradation products greatly genetic or protein manipulations. contribute to flavor or to off-flavors Altered survival characteristics: (Rijnen et al, Appl. Environ. survival of industrial processes, Microbiol. 65:4873-4880, 1999). growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance.
  • RNA arsenate reductase (EC 1.97.1.5). and/or protein, fusion protein YqcM reduces the arsenate ion production, genetic modification, (H 2 AsO) to arsenite ion (AsO).
  • H 2 AsO genetic modification
  • AsO arsenite ion
  • mutagenesis amplification of Arsenate is an abundant oxyanion genetic material or for other that, because of its ability to mimic genetic or protein manipulations. the phosphate group, is toxic to cells. Production of desirable flavors.
  • Arsenate reductase participates to Modified flavor, aroma and/or achieve arsenate resistance in both texture attributes.
  • arsenate to arsenite is survival of industrial processes, then exported by a specific growth or storage in product transporter.
  • Arsenite reductase is formats, persistence in gut coupled to the glutathione and environment.
  • glutaredoxin system for its enzyme Altered viability in response to activity (Bennett et al, Proc. Natl. stress conditions. icad. Sci. USA 98:13577-13582, Altered metabolic properties or 2001). regulation of metabolic pathways.
  • Altered probiotic attributes Improved fermentation properties or other industrially useful processes.
  • Modified health properties including immunoregulatory, anticancer, gut health).4 135 [Altered amino acid metabolism. [Homologue of cna, encoding a SEQ SEQ ED NO: NO: Utility Description
  • RNA RNA potential use in the dairy industry as a and/or protein
  • fusion protein cheese-ripening agent since proline production, genetic modification, release from prolme-containing mutagenesis amplification of peptides in cheese reduces bitterness genetic material or for other
  • bacteria is essential for bacterial Altered survival characteristics: growth in milk but also for the survival of industrial processes, development of the organoleptic growth or storage in product properties of dairy products.
  • PepQ is formats, persistence in gut involved both in bacterial growth by environment. supplying amino acids, and in the Altered metabolic properties or development of flavor in dairy regulation of metabolic products, by hydrolyzing peptides
  • DNA Polypeptide growth or storage in product contribute to flavor or to off-flavors formats, persistence in gut (Rijnen et al, Appl. Environ. environment. Microbiol. 65:4873-4880, 1999).
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties D ⁇ other industrially useful processes.
  • the hisH subunit for controlled expression u o.f ⁇ RNA provides the glutamine and/or protein, fusion protein amidotransferase activity that production, genetic modification produces the ammonia necessary to mutagenesis amphfication of hisF for the synthesis of IGP and genetic material or for other [AICAR.
  • HD NO NO Utility Description DNA Polypeptide genetic or protein manipulations, of amino acids in cheese plays a Altered survival characteristics: major role in cheese flavor survival of industrial processes, development. Amino acid growth or storage in product degradation products greatly formats, persistence in gut contribute to flavor or to off-flavors environment. (Rijnen et al, Appl. Environ. Altered metabolic properties. Microbiol. 65:4873-4880, 1999). Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance.
  • RNA nucleoside-diphosphate kinase (EC and/or protein, fusion protein 2.7.4.6), which converts production, genetic modification, (deoxy)ribonucleoside diphosphates mutagenesis amphfication of into their co ⁇ esponding genetic material or for other triphosphates.
  • NdK is an ubiquitous genetic or protein manipulations. and nonspecific enzyme but is an Production of desirable flavors. important cellular enzyme that Modified flavor, aroma and/or monitors and maintains nucleotide texture attributes.
  • Altered survival characteristics number of regulatory processes, survival of industrial processes, including signal transduction, growth or storage in product development and cell surface formats, persistence in gut polysaccharide synthesis. environment. Altered viability in response to stress conditions. Altered metabolic properties or regulation of metabolic pathways.
  • Altered probiotic attributes. 50 142 Altered cell wall or cell surface Homologue of PrtB, a Pfl-type characteristics, structures or proteinase precursor (Lactocepin) functions. also called ceU wall-associated serine Modified adhesion to human or proteinase (EC 3.4.21.96). PrtB animal cells or ceU lines. breaks down milk proteins during the Production of desirable flavors.
  • RNA is best known for its action on and/or protein, fusion protein caseins, although it has been shown production, genetic modification, to hydrolyze hemoglobin and SEQ SEQ ED NO: NO: Utility Description
  • Lactocepin genetic material or for other is a type I membrane protein, located genetic or protein manipulations. in the cell wall and belongs to Altered survival characteristics: peptidase family S8; also known as survival of industrial processes, the Subtilase Family. Lactocepin is growth or storage in product responsible for the hydrolysis of formats, persistence in gut casein in milk and specificity environment. differences between lactocepins from Altered metabolic properties. different starter strains may be partly Altered probiotic attributes. responsible for imparting different Modified health properties flavor qualities to cheese (Broadbent (including immunoregulatory, et al, Appl. Environ. Microbiol. anticancer, gut health). 68:1778-1785, 2002). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes.
  • the enzymatic Altered survival characteristics degradation of amino acids in cheese survival of industrial processes, plays a major role in cheese flavor growth or storage in product development.
  • Amino acid formats, persistence in gut degradation products greatly environment. contribute to flavor or to off-flavors Altered metabolic properties. (Rijnen et al, Appl. Environ. Altered probiotic attributes. Microbiol. 65:4873-4880, 1999).
  • Modified health properties including immunoregulatory, anticancer, gut health).
  • Modified antibiotic resistance Improved fermentation properties or other industrially useful processes.2 144 [Production of desirable flavors.
  • IolF transports myo- Construction of genetic vectors inositol into the bacterial cell. IolF is for controlled expression of RNA part of the iol operon of the myo- and/or protein, fusion protein inositol catabolism pathway. Myo- production, genetic modification, inositol is abundant in nature, mutagenesis amplification of especially in soil. Various genetic material or for other microorganisms are able to grow on genetic or protein manipulations.
  • myo-inositol as the sole carbon Altered survival characteristics: source.
  • the expression of the iol survival of industrial processes, operon is under glucose repression growth or storage in product (Miwa and Fujita, J. Bacteriol. formats, persistence in gut 183:5877-5884, 2001). environment.
  • Altered metabolic properties Modified carbohydrate levels or functional properties.
  • 54 146 Altered cell wall or cell surface Homologue of mga4, a positive characteristics, structures or regulatory protein that acts as a functions.
  • RNA associated/virulence factors, and/or protein, fusion protein production, genetic modification, mutagenesis amplification of genetic material or for other genetic or protein manipulations. Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut SEQ SEQ IDD NO NO: Utility Description
  • DNA Polypeptide environment Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. Regulation of polysaccharide production, adhesion, immune modulation. 55 147 Altered amino acid metabolism. Homologue of BH3554, encoding a Removal of undesirable flavor carboxylesterase (3.1.1.1). BH3554 characteristics. hydrolyzes carboxylic ester bonds Production of desirable flavors. with relatively broad substrate Modified flavor, aroma and/or specificity. It is involved in amino texture attributes. acid metabolism and flavor.
  • RNA ino acids for controlled expression of RNA in cheese plays a major role in cheese and/or protein, fusion protein flavor development.
  • Amino acid production, genetic modification, degradation products greatly mutagenesis amplification of contribute to flavor or to off-flavors genetic material or for other (Rijnen et al, Appl. Environ. genetic or protein manipulations. Microbiol. 65:4873-4880, 1999).
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut enviromnent.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes.
  • DNA Polypeptide Construction of genetic vectors in cheese plays a major role in cheese for controlled expression of RNA flavor development.
  • Amino. acid and/or protein, fusion protein degradation products greatly production, genetic modification, contribute to flavor or to off-flavors mutagenesis amplification of (Rijnen et al, Appl. Environ. genetic material or for other Microbiol. 65:4873-4880, 1999).
  • genetic or protein manipulations Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved fermentation properties or other industrially useful processes.
  • TmpA plays a role in adhesion and is Modified adhesion to human or part of an operon containing the animal cells or cell lines. mapA gene. Production of desirable flavors. Modified flavor, aroma and/or texture attributes. Construction of genetic vectors for controlled expression of RNA and/or protein, fusion protein production, genetic modification, mutagenesis amplification of genetic material or for other genetic or protein manipulations. Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, [anticancer, gut health).
  • Free fatty acids are important mutagenesis amplification of in providing flavor-bearing genetic material or for other compounds for dairy products such as genetic or protein manipulations. cheese, and have a significant role in Altered survival characteristics: both flavor and texture. Used survival of industrial processes, extensively in wide range of growth or storage in product convenience foods. Short chain fatty formats, persistence in gut acids are known to have a variety of environment. health impacts. Altered metabolic properties. Modified lipid, glycolipid or free fatty acid levels or functional properties. Modified production of short chain fatty acids. Altered lipid metabolism. Altered probiotic attributes.
  • Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health) 62 154 Altered ceU wall or cell surface Homologue of aggH, encoding an characteristics, stmctures or autoaggregation mediating protein. functions.
  • AggH contains a region of similarity Modified adhesion to human or to ATP-dependent DEAD-box animal cells or ceU fines. helicase. The protein is involved in Production of desirable flavors. genetic exchange, pathogen exclusion Modified flavor, aroma and/or and persistence in the gut texture attributes. environment by promoting SEQ SEQ ED NO NO: Utility Description
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. Improved fermentation properties or other industrially useful processes.
  • Altered survival characteristics 183:5877-5884, 2001) survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Modified carbohydrate levels or functional properties.
  • the expression of the genetic material or for other iol operon is under glucose repression genetic or protein manipulations.
  • citrate lyase phosphoribosyl- Modified flavor, aroma, texture dephospho-CoA transferase (Apo- attributes. ACP nucleodityltransferase; EC Construction of genetic vectors 2.8.3.10).
  • the transferase belongs to for controlled expression of RNA the citX family (Schneider et al, and/or protein, fusion protein Biochem. 39:9438-9450, 2000). production, genetic modification, Carbohydrate metabolism impacts on mutagenesis amplification of flavor, functionality and survival as genetic material or for other weU as growth. genetic or protein manipulations. Altered survival characteristics: SEQ SEQ ID NO: NO: Utility Description
  • DNA Polypeptide (survival of industrial processes, growth or storage in product formats, persistence in gut environment). Modified carbohydrate levels or functional properties. Altered metabolic properties. Modified citrate metabolism. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes.
  • pymvate carboxylase which Modified flavor, aroma, texture catalyzes a two-step reaction, attributes. involving the ATP-dependent Construction of genetic vectors carboxylation of the covalently for controlled expression of RNA attached biotin in the first step and and or protein, fusion protein the transfer of the carboxyl group to production, genetic modification, pymvate to generate oxaloacetate in mutagenesis amplification of the second.
  • the enzyme is involved genetic material or for other in gluconeogenesis and amino acid genetic or protein manipulations. biotransformations.
  • Carbohydrate Altered survival characteristics metabolism impacts on flavor, (survival of industrial processes, functionality and survival as well as growth or storage in product growth. formats, persistence in gut environment). Modified carbohydrate levels or functional properties. Altered metabolic properties. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health) Improved fermentation properties or other industrially useful processes.6 160 Production of desirable flavors. Homologue of fox3, encoding a 3- Modified flavor, aroma and/or oxoacyl-coenzyme A thiolase (EC SEQ SEQ ED)
  • Altered survival characteristics flavor-bearing compounds for dairy survival of industrial processes, products such as cheese, and have a growth or storage in product significant role in both flavor and formats, persistence in gut texture. Used extensively in wide environment. range of convenience foods.
  • Short Altered metabolic properties chain fatty acids are known to have a Modified lipid, glycolipid or free variety of health impacts. fatty acid levels or functional properties. Modified production of short chain fatty acids.
  • Altered probiotic attributes Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes.
  • H O Utility Description DNA Polypeptide regulation of metabolic pathways. Altered probiotic attributes. 68 162 Production of desirable flavors. Homologue of SC6F7, encoding a Modified flavor, aroma and/or lipase. Lipases are involved in the texture attributes. breakdown of triglycerides, Constmction of genetic vectors metabolism, growth, production of for controlled expression of RNA flavor compounds, and the release of and/or protein, fusion protein free fatty acids. Can also catalyze production, genetic modification. esterification of glycerol to form mutagenesis amplification of mono, di- and triglycerides. Free fatty genetic material or for other acids are important in providing genetic or protein manipulations.
  • flavor-bearing compounds for dairy Altered survival characteristics products such as cheese, and have a survival of industrial processes, significant role in both flavor and growth or storage in product texture. Used extensively in wide formats, persistence in gut range of convenience foods.
  • Short environment. chain fatty acids are known to have a Altered metabolic properties. ariety of health impacts. Modified lipid, glycolipid or free fatty acid levels or functional properties. Modified production of short chain fatty acids.
  • YohH is involved in techoic acid Modified adhesion to human or synthesis, and important for cell wall animal cells or cell lines. functions including adhesion, Production of desirable flavors. immune cell interaction, product Modified flavor, aroma and/or texture. texture attributes. Construction of genetic vectors for controlled expression of RNA and/or protein, fusion protein production, genetic modification, SEQ SEQ ED
  • DNA Polypeptide mutagenesis amplification of genetic material or for other genetic or protein manipulations Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Modified antibiotic resistance. Improved antimicrobial properties. Improved fermentation properties or other industrially useful processes. 69 164 Altered cell wall or cell surface Homologue of yohJ, encoding a characteristics, structures or lipopolysaccharide biosynthesis functions. protein. YohJ is involved in techoic Modified adhesion to human or acid synthesis, and important for cell animal cells or cell lines. wall functions including adhesion, Production of desirable flavors.
  • Pst is a multisubunit mutagenesis amplification of system and belongs to the ABC genetic material or for other superfamily of transporters (Novak et genetic or protein manipulations. al, J Bacteriol. 181:1126-1133, Production of desirable flavors. 1999).
  • Intracellular phosphate levels Modified flavor, aroma and/or influence survival of bacteria in texture attributes.
  • Altered survival characteristics are involved in the stringent response. survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered viability in response to stress conditions. Altered metabolic properties or regulation of metabolic pathways. Altered probiotic attributes. 71 166 Altered cell wall or cell surface Homologue of oppA, encoding an characteristics, structures or integral membrane protein of the functions. oligopeptide transport system (Opp) Production of bioactive or of Lactococcus lactis. Opp proteins functional polypeptides. and the proteinase PrtP are important Modified adhesion to human or components of the proteolytic system animal cells or cell lines. The Opp system belongs to the Altered amino acid metabolism.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (mcluding immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful irocesses. SEQ SEQ ED
  • protein (Detmers et al, Proc. Natl. Construction of genetic vectors Acad. Sci. USA 97:12487-12492, for controlled expression of RNA 2000).
  • fusion protein supply of amino acids to bacteria, and; production, genetic modification, the resultant production of flavorful mutagenesis amplification of or functional amino-acid degradation genetic material or for other products. genetic or protein manipulations.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes.
  • Modified health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes.
  • 71 Altered cell wall or cell surface Homologue of OppF, encoding an characteristics, stmctures or integral membrane protein of the functions.
  • oligopeptide transport system (Opp) Production of bioactive or of Lactococcus lactis.
  • Opp proteins functional polypeptides. and the proteinase PrtP are important Modified adhesion to human or components of the proteolytic system, animal cells or cell lines.
  • the Opp system belongs to the Altered amino acid metabolism. superfamily of ABC transporters and Removal of undesirable flavor consists of five proteins: the integral characteristics.
  • membrane proteins OppB and OppC Production of desirable flavors.
  • the ATP-binding proteins OppD and Modified flavor, aroma and/or OppF, and the OppA a receptor SEQ SEQ ED NO NO: Utility Description
  • DNA Polypeptide texture attributes protein (Detmers et al, Proc. Natl Construction of genetic vectors Acad. Sci. USA 97:12487-12492, for controlled expression of RNA 2000). Important for the uptake and and/or protein, fusion protein supply of amino acids to bacteria, and production, genetic modification, the resultant production of flavorful mutagenesis amplification of or functional amino-acid degradation genetic material or for other products. genetic or protein manipulations. Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health). Improved fermentation properties or other industrially useful processes.
  • thdF is characteristics. involved in the oxidation of Modified flavor, aroma, texture derivatives of the sulphur-containing attributes. heterocycle thiophene and is induced Construction of genetic vectors during stationary phase.
  • the thdF for controlled expression of RNA gene is subject to substantial and/or protein, fusion protein catabolite repression by glucose and production, genetic modification, its expression is also greatly mutagenesis amplification of decreased in the absence of oxygen genetic material or for other (Zabel etal, Microbios. 101 :89-103, genetic or protein manipulations. ⁇ ooo).
  • Altered survival characteristics (survival of industrial processes, growth or storage in product formats, persistence in gut environment). Altered metabolic properties. Modified metabohsm of sulphur- containing compounds. Altered probiotic attributes. Organisms or materials with improved health properties (including immunoregulatory, anticancer, gut health).
  • RNA pymvate oxidase (EC 1.2.3.3), which and/or protein, fusion protein decarboxylates pyruvate.
  • the enzyme production, genetic modification, is a flavoprotein (FAD) requiring mutagenesis amphfication of thiamine diphosphate and is genetic material or for other important for aerobic growth and genetic or protein manipulations. survival in aerobic conditions. Production of desirable flavors. Carbohydrate metabolism impacts on Modified flavor, aroma and/or flavor, functionality and survival as texture attributes. well as growth. Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered survival characteristics survival of industrial processes, growth or storage in product formats, persistence in gut environment.
  • Altered metabolic properties Increased folate production.
  • Altered probiotic attributes Modified health properties (including immunoregulatory, anticancer, gut health). Protection of intestinal cells from SEQ SEQ ID NO: NO: Utility Description
  • DNA Polypeptide toxic compounds Modified antibiotic resistance. Improved fermentation properties r other industrially useful processes. 77 176 Altered amino acid metabolism. Homologue of trpA, encoding the Removal of undesirable flavor tryptophan synthase alpha chain (EC characteristics. 4.2.1.20). TrpA catalyzes the Production of desirable flavors. Formation of indole from the cleavage Modified flavor, aroma and/or of 3-indolyl-D-glyceraldehyde 3'- texture attributes. phosphate. Seven structural genes are Construction of genetic vectors required for tryptophan biosynthesis: for controlled expression of RNA trpABCDEFG.
  • TrpA encodes the and/or protein, fusion protein tryptophan synthase alpha chain (EC production, genetic modification, 4.2.1.20) Tryptophan is important for mutagenesis amplification of flavor development.
  • Amino acid genetic material or for other degradation products greatly genetic or protein manipulations. contribute to flavor or to off-flavors Altered survival characteristics: (Rijnen et al, Appl. Environ. survival of industrial processes, Microbiol. 65:4873-4880, 1999). growth or storage in product formats, persistence in gut environment. Altered metabolic properties. Altered probiotic attributes. Modified health properties (including immunoregulatory, anticancer, gut health), M ei dified antibiotic resistance.
  • TrpB catalyzes the Production of desirable flavors. condensation of indole to a serine- Modified flavor, aroma and/or derived arninoacrylate moiety bound texture attributes. to pyridoxal phosphate. Seven Constmction of genetic vectors structural genes are required for for controlled expression of RNA tryptophan biosynthesis: and/or protein, fusion protein trpABCDEFG. TrpB encodes the production, genetic modification, tryptophan synthase beta chain (EC mutagenesis amplification of 4.2.1.20).
  • Tryptophan is important for genetic material or for other flavor development. Amino acid genetic or protein manipulations, degradation products greatly Altered survival characteristics: contribute to flavor or to off-flavors survival of industrial processes, (Rijnen et al, Appl. Environ. growth or storage in product Microbiol. 65:4873-4880, 1999). SEQ SEQ ED
  • TrpC catalyzes the ring closure of ⁇ - Construction of genetic vectors (2-carboxyphenylamino)- 1 - for controlled expression of RNA deoxyribulose 5'-phosphate to and/or protein, fusion protein indoleglycerol phosphate, the fifth reduction, genetic modification, step in the pathway of tryptophan mutagenesis amplification of biosynthesis from chorismate. Seven genetic material or for other structural genes are required for genetic or protein manipulations. tryptophan biosynthesis: Altered survival characteristics: trpABCDEFG. Tryptophan is survival of industrial processes, important for flavor development. growth or storage in product Amino acid degradation products formats, persistence in gut greatly contribute to flavor or to off- environment.
  • RNA phosphorylase PNP
  • fusion protein PNP catalyzes the reversible production, genetic modification, phosphorolysis of (2'-deoxy)purine mutagenesis amplification of ribonucleosides to free base and (2'- genetic material or for other deoxy)ribose-l -phosphate and has a genetic or protein manipulations. metabolic role in purine salvage. Production of desirable flavors. Intracellular phosphate levels Modified flavor, aroma and/or influence survival of bacteria in jtexture attributes. [environmental stress conditions, and SEQ SEQ ID
  • Modified flavor, aroma and/or texture attributes Altered survival characteristics: survival of industrial processes, growth or storage in product formats, persistence in gut environment. Altered viability in response to stress conditions. Altered metabolic properties or regulation of metabolic pathways. [Altered probiotic attributes. 80 183 Altered cell wall or cell surface Homologue of lysostaphin, an characteristics, stmctures or antimicrobial immunity factor of functions. Staphylococcus simulans biovar Improved antimicrobial staphylolyticus active against properties Staphylococcus aureas. Lysostaphin Modified adhesion to human or is currently being investigated for use animal ceUs or ceU lines. against mastitis in dairy cattle, caused Production of desirable flavors.
  • Isolated polynucleotides of the present invention include the polynucleotides identified herein as SEQ ID NOS: 1-80; isolated polynucleotides comprising a polynucleotide sequence selected from the group consisting of SEQ ID NOS: 1-80; isolated polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ) NOS: 1-80; isolated polynucleotides comprising a polynucleotide sequence that is complementary to any of the above polynucleotides; isolated polynucleotides comprising a polynucleotide sequence that is a reverse sequence or a reverse complement of any of the above polynucleotides; antisense sequences corresponding to any of the above polynucleotides; and variants of any of the above polynucleotides, as that term is described in this specification.
  • polynucleotide(s), means a single or double stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and conesponding RNA molecules, including mRNA molecules, both sense and antisense strands of DNA and RNA molecules, and comprehends cDNA, genomic DNA and recombinant DNA, as weU as wholly or partially synthesized polynucleotides.
  • a polynucleotide of the present invention may be an entire gene, or any portion thereof.
  • a gene is a DNA sequence which codes for a functional protein or RNA molecule.
  • Operable antisense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide” therefore includes all operable antisense fragments.
  • Antisense polynucleotides and techniques involving antisense polynucleotides are well known in the art and are described, for example, in Robinson-Benion, et al., "Antisense techniques,” Methods in Enzymol. 254(23): 363-375, 5 1995; and Kawasaki, et al.,Artif ⁇ c. Organs 20 (8): 836-848, 1996.
  • complement For the sequence 5' AGGACC 3', the complement, reverse complement, and reverse sequences are as follows: complement 3 ' TCCTGG 5 ' reverse complement 3' GGTCCT 5' reverse sequence 5' CCAGGA 3' Identification of genomic DNA and heterologous species DNA can be accomphshed by standard DNA/DNA hybridization techniques, under appropriately stringent conditions, using all or part of a DNA sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using oligonucleotide primers that are designed based on known DNA and protein sequences can be used to amplify and identify other identical or similar DNA sequences.
  • Synthetic DNA corresponding to the identified sequences or variants thereof may be produced by conventional synthesis methods.
  • AU of the polynucleotides described herein are isolated and purified, as those terms are commonly used in the art.
  • the polynucleotides identified as SEQ ID NOS: 1-80 contain open reading frames ("ORFs"), or partial open reading frames, encoding polypeptides. Additionally, polynucleotides identified as SEQ JJD NOS: 1-80 may contain non-coding sequences such as promoters and terminators that may be useful as control elements. Additionally, open reading frames encoding polypeptides may be identified in extended or full-length sequences corresponding to the sequences set out as SEQ JJD NOS: 81-183.
  • Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the location of known start and stop codons, most likely reading frame identification based on codon frequencies, similarity to known bacterial expressed genes, etc. Tools and software suitable for ORF analysis include GeneWise (The Sanger Center, WeUcome Trust Genome Campus, Hinxton, Cambridge CB10 ISA, United Kingdom), Diogenes (Computational Biology Centers, University of Minnesota, Academic Health Center, UMHG Box 43 Minneapolis MN 55455), and GRAIL (Informatics Group, Oak Ridge National Laboratories, Oak Ridge, Tennessee, TN). Open reading frames and portions of open reading f ames may be identified in the polynucleotides of the present invention.
  • the polynucleotide may be extended in the area of the partial open reading frame using techniques that are well known in the art until the polynucleotide for the full open reading frame is identified.
  • polynucleotides and open reading frames encoding polypeptides may be identified using the polynucleotides of the present invention.
  • the open reading frames may be isolated and/or synthesized. Expressible genetic constructs comprising the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art, may then be constructed.
  • oligonucleotide refers to a relatively short segment of a polynucleotide sequence, generally comprising between 6 and 60 nucleotides, and comprehends both probes for use in hybridization assays and primers for use in the amplification of DNA by polymerase chain reaction.
  • the term "; -mer,” with reference to a specific value of "x,” refers to a polynucleotide comprising at least a specified number (" ") of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-80.
  • the value of* may be from about 20 to about 600, depending upon the specific sequence.
  • the present invention provides isolated polypeptides encoded, or partially encoded, by the above polynucleotides.
  • such polypeptides comprise a sequence selected from the group consisting of SEQ ID NO: 81-183, and variants thereof.
  • polypeptide encompasses amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide bonds.
  • polypeptide encoded by a polynucleotide includes polypeptides encoded by a polynucleotide which comprises an isolated polynucleotide sequence or variant provided herein.
  • Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated with bacterial, fungal, mammalian or other eukaryotic carbohydrates or may be non-glycosylated.
  • Polypeptides of the present invention may be produced recombinantly by inserting a polynucleotide that encodes the polypeptide into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polypeptide encoding a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are Escherichia coli, Lactococcus lactis, Lactobacillus, insect, yeast or a mammalian cell line such as COS or CHO.
  • polypeptides may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.
  • polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence encoded by a polynucleotide of the present invention.
  • a "functional portion" of a polypeptide is that portion which contains the active site essential for affecting the function of the polypeptide, for example, the portion of the molecule that is capable of binding one or more reactants.
  • the active site may be made up of separate portions present on one or more polypeptide chains and wUl generally exhibit high binding affinity.
  • Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using, for example, the representative assays provided below. Portions and other variants of the inventive polypeptides may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques that are well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the
  • the polypeptides are at least about 80% pure; more preferably at least about 90% pure; and most preferably at least about 99% pure.
  • the term "variant” comprehends polynucleotide or polypeptide sequences different from the specifically identified sequences, wherein one or more nucleotides or amino acid residues is deleted, substituted, or added. Variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant polynucleotide sequences preferably exhibit at least 60%, more preferably at least 75%, more preferably yet at least 90%, and most preferably at least 95% identity to a sequence of the present invention.
  • Variant polypeptide sequences preferably exhibit at least 60%, more preferably at least 75%, more preferably yet at least 90%, and most preferably at least 95% identity to a sequence of the present invention.
  • the percentage identity is determined by aligning the two sequences to be compared as described below, dete ⁇ rnning the number of identical residues in the aligned portion, dividing that number by the total number of residues in the inventive (queried) sequence, and multiplying the result by 100.
  • Polynucleotide and polypeptide sequences may be aligned, and the percentage of identical residues in a specified region may be determined against another polynucleotide or polypeptide, using computer gorithms that are publicly available.
  • Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms.
  • Polynucleotides may also be analyzed using the BLASTX algorithm, which compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database. The percentage identity of polypeptide sequences may be examined using the BLASTP algorithm.
  • the BLASTN, BLASTX and BLASTP programs are avaUable on the NCBI anonymous FTP server and from the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20894, USA.
  • the BLASTN algorithm Version 2.0.4 [Feb-24-1998], Version 2.0.6 [Sept-16-1998] and Version 2.0.11 [Jan-20-2000], set to the parameters described below, is preferred for use in the determination of polynucleotide variants according to the present invention.
  • the BLASTP algorithm, set to the parameters described below, is prefened for use in the determination of polypeptide variants according to the present invention.
  • the use of the BLAST family of algorithms, including BLASTN, BLASTP and BLASTX, is described in the publication of Altschul et al, Nucleic Acids Res. 25: 3389-3402, 1997.
  • FASTA The computer algorithm FASTA is available on the Internet and from the University of Virginia by contacting David Hudson, Vice Provost for Research, University of Virginia, P.O. Box 9025, Charlottesville, VA 22906-9025, USA.
  • FASTA Version 2.0u4 [February 1996], set to the default parameters described in the documentation and distributed with the algorithm, may be used in the determination of variants according to the present invention.
  • the use of the FASTA algorithm is described in Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444-2448, 1988; and Pearson , Methods in Enzymol. 183: 63-98, 1990.
  • the following running parameters are prefened for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity for polynucleotide sequences: Unix running command: blastall -p blastn -d embldb -e 10 -GO -E0 -r 1 -v 30 -b 30 -i queryseq -o results; the parameters are: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]
  • the following running parameters are prefened for determination of alignments and similarities using BLASTP that contribute to the E values and percentage identity of polypeptide sequences: blastall -p blastp -d swissprottrembledb -e 10 -G 0 -E 0 -v 30 -b 30 -i queryseq -o results; the parameters are: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -v Number of one-line descriptions (v) [Integer]; -b Number of alignments to show (b) [Integer]; -I Query File [File In]; -o BLAST report Output File [File Out] Optional.
  • the "hits" to one or more database sequences by a queried sequence produced by BLASTN, FASTA, BLASTP or a similar algorithm align and identify similar portions of sequences.
  • the hits are a ⁇ anged in order of the degree of similarity and the length of sequence overlap.
  • Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.
  • the BLASTN, FASTA, and BLASTP algorithms also produce "Expect" values for alignments.
  • the Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size.
  • the Expect value is used as a significance threshold for determining whether the hit to a database, such as the prefened EMBL database, indicates true similarity.
  • a database such as the prefened EMBL database
  • an E value of 0.1 assigned to a polynucleotide hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance.
  • the aligned and matched portions of the polynucleotide sequences then have a probability of 90% of being the same.
  • variant polynucleotides and polypeptides preferably comprise sequences producing an E value of 0.01 or less when compared to the polynucleotide or polypeptide of the present invention.
  • a variant polynucleotide or polypeptide is any sequence that has at least a 99% probability of being the same as the polynucleotide or polypeptide of the present invention, measured as having an E value of 0.01 or less using the BLASTN, FASTA, or BLASTP algorithms set at parameters described above.
  • a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at parameters described above.
  • a variant polypeptide is a sequence having the same number or fewer amino acids than a polypeptide of the present invention that has at least a 99% probability of being the same as a polypeptide of the present invention, measured as having an E value of 0.01 or less using the BLASTP algorithm set at the parameters described above.
  • the percentage identity is determined by aligning sequences using one of the BLASTN, FASTA, or BLASTP algorithms, set at the running parameters described above, and identifying the number of identical nucleic or amino acids over the aligned portions; dividing the number of identical nucleic or amino acids by the total number of nucleic or amino acids of the polynucleotide or polypeptide sequence of the present invention; and then multiplying by 100 to determine the percentage identity.
  • a polynucleotide of the present invention having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the alignment produced by the BLASTN algorithm using the parameters described above.
  • the 5 23 nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide.
  • the percentage identity of the polynucleotide of the present invention to the hit in the EMBL library is thus 21/220 times 100, or 9.5%.
  • the polynucleotide sequence in the EMBL database is thus not a variant of a polynucleotide of the present invention.
  • variant polynucleotides and polypeptides preferably have additional structure and/or functional features in common with the inventive polynucleotide or polypeptide.
  • Polypeptides having a specified degree of identity to a polypeptide of the present invention share a high degree of similarity in their primary structure and have substantially similar functional properties.
  • polynucleotides having a specified degree of identity to, or capable of hybridizing to an inventive polynucleotide preferably have at least one of the following features: (i) they contain an open reading frame or partial open reading frame encoding a polypeptide having substantially the same functional properties as the polypeptide encoded by the inventive polynucleotide; or (ii) they contain identifiable 20 domains in common.
  • variant polynucleotides of the present invention hybridize to the polynucleotide sequences recited in SEQ ID NOS: 1-80, or complements, reverse sequences, or reverse complements of those sequences under stringent conditions.
  • stringent conditions refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 25 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in IX SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.
  • the present invention also encompasses polynucleotides that differ from the disclosed sequences but that, as a consequence of the discrepancy of the genetic code, encode a polypeptide having similar enzymatic activity as a polypeptide encoded by a polynucleotide of 0 the present invention.
  • polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-80, or complements, reverse sequences, or reverse complements of those sequences as a result of conservative substitutions are encompassed within the present invention.
  • polynucleotides comprising sequences that differ from the inventive polynucleotide sequences or complements, reverse complements, or reverse sequences as a result of deletions, and/or insertions totaling less than 10% of the total sequence length are also contemplated by and encompassed within the present invention.
  • polypeptides comprising sequences that differ from the inventive polypeptide sequences as a result of amino acid substitutions, insertions, and/or deletions totaling less than 10% of the total sequence length are contemplated by and encompassed v thin the present invention, provided the variant polypeptide has similar activity to the inventive polypeptide.
  • the polynucleotides of the present invention may be isolated from various libraries, or may be synthesized using techniques that are well known in the art.
  • the polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g., Beckman Oligo 1000M DNA Synthesizer) to obtain polynucleotide segments of up to 50 or more nucleic acids.
  • a plurality of such polynucleotide segments may then be ligated using standard DNA manipulation techniques that are well known in the art of molecular biology.
  • One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5-nucleotide overhang. The next segment may then be synthesized in a similar fashion, with a 5-nucleotide overhang on the opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely in vitro.
  • polynucleotides identified as SEQ ID NOS: 1-80 are generally refened to as "partial" sequences, in that they may not represent the full coding portion of a gene encoding a naturally occurring polypeptide.
  • the partial polynucleotide sequences disclosed herein may be employed to obtain the conesponding full-length genes for various species and organisms by, for example, screening DNA expression libraries using hybridization probes based on the polynucleotides of the present invention, or using PCR amplification with primers based upon the polynucleotides of the present invention.
  • polynucleotide of the present invention upstream and downstream of the conesponding DNA, as well as identify the co ⁇ esponding mRNA and genomic DNA, including the promoter and enhancer regions, of the complete gene.
  • the present invention thus comprehends isolated polynucleotides comprising a sequence identified in SEQ ID NOS: 1-80, or a variant of one of the specified sequences, that encode a functional polypeptide, including full length genes.
  • Such extended polynucleotides may have a length of from about 50 to about 4,000 nucleic acids or base pairs, and preferably have a length of less than about 4,000 nucleic acids or base pairs, more preferably yet a length of less than about 3,000 nucleic acids or base pairs, more preferably yet a length of less than about 2,000 nucleic 5 acids or base pairs.
  • extended polynucleotides of the present invention may have a length of less than about 1,800 nucleic acids or base pairs, preferably less than about 1,600 nucleic acids or base pairs, more preferably less than about 1,400 nucleic acids or base pairs, more preferably yet less than about 1,200 nucleic acids or base pairs, and most preferably less than about 1 ,000 nucleic acids or base pairs.0
  • Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ DD NOS: 1-80 or their variants.
  • polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a - polynucleotide identified as SEQ ED NOS: 1-80 or a variant of one of the polynucleotides identified as SEQ ID NOS : 1 -80.
  • Oligonucleotide probes and primers complementary to and/or conesponding to SEQ D NOS: 1-80, and variants of those sequences, are also comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest.
  • An oligonucleotide probe or primer is described as "conesponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-80 or a variant, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-80 or a variant of one of the specified sequences.
  • Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least 90% to 95%, and more preferably at least 98% to 100%, of the nucleotides of the other strand.
  • substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions.
  • Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less than about 500 mM and preferably less than about 200 mM.
  • Hybridization temperatures can be as low as 5°C, but are generaUy greater than about 22°C, more preferably greater than about 30°C and most preferably greater than about 37°C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by other factors such as probe composition, presence of organic solvents and extent of base ntismatching, the combination of parameters is more important than the absolute measure of any one alone.
  • DNA-DNA hybridization studies may be performed using either genomic DNA or DNA derived by preparing cDNA from the RNA present in a sample to be tested. In addition to DNA-DNA hybridization, DNA-RNA or RNA-RNA hybridization assays are also possible.
  • the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a polynucleotide sequence of the present invention. Probes and primers of the present invention may be from about 8 to 100 base pairs in length or, preferably from about 10 to 50 base pairs in length or, more preferably from about 15 to 40 base pairs in length.
  • the primers and probes may be readily selected using procedures well known in the art, taking into account DNA-DNA hybridization stringencies, annealing and melting temperatures, potential for formation of loops and other factors, which are well known in the art.
  • Tools and software suitable for designing probes, and especially for designing PCR primers are available from Premier Biosoft International, 3786 Corina Way, Palo Alto, CA 94303-4504. Prefened techniques for designing PCR primers are also disclosed in Dieffenbach and Dyksler, PCR primer: a laboratory manual, CSHL Press: Cold Spring Harbor, NY, 1995.
  • a plurality of oligonucleotide probes or primers conesponding to a polynucleotide of the present invention may be provided in a kit form.
  • kits generally comprise multiple DNA or oligonucleotide probes, each probe being specific for a polynucleotide sequence.
  • Kits of the present invention may comprise one or more probes or primers conesponding to a polynucleotide of the present invention, including a polynucleotide sequence identified in SEQ ID NOS: 1-80.
  • the oligonucleotide probe kits of the present invention comprise multiple probes in an a ⁇ ay format, wherein each probe is immobilized in a predefined, spatially addressable location on the surface of a solid substrate.
  • Array formats which may be usefully employed in the present invention are disclosed, for example, in U.S. Patents No.
  • Oligonucleotide probes for use in the present invention may be constructed syntheticaUy prior to immobilization on an a ⁇ ay, using techniques well known in the art (See, for example, Gait, ed., Oligonucleotide synthesis a practical approach, IRL Press: Oxford, England, 1984). Automated equipment for the synthesis of oligonucleotides is available commercially from such companies as Perkin Elmer/Applied Biosystems Division (Foster City, CA) and may be operated according to the manufacturer's instructions.
  • the probes may be constructed directly on the surface of the a ⁇ ay using techniques taught, for example, in PCT Publication No. WO 95/00530.
  • the solid substrate and the surface thereof preferably form a rigid support and are generally formed from the same material.
  • materials from which the solid substrate may be constructed include polymers, plastics, resins, membranes, polysaccharides, silica or silica-based materials, carbon, metals and inorganic glasses.
  • Synthetically prepared probes may be immobilized on the surface of the solid substrate using techniques well known in the art, such as those disclosed in U.S. Patent No. 5,412,087.
  • compounds having protected functional groups such as thiols protected with photochemically removable protecting groups
  • Selected regions of the surface are then i ⁇ adiated with a light source, preferably a laser, to provide reactive thiol groups.
  • a light source preferably a laser
  • This inadiation step is generally performed using a mask having apertures at predefined locations using photolithographic techniques well known in the art of semiconductors.
  • the reactive thiol groups are then incubated with the oligonucleotide probe to be immobilized.
  • the precise conditions for incubation such as temperature, time and pH, depend on the specific probe and can be easily determined by one of skill in the art.
  • each oligonucleotide probe is typically immobilized in a discrete area of less than about 1 mm 2 . Preferably each discrete area is less than about 10,000 mm 2 , more preferably less than about 100 mm 2 . In this manner, a multitude of oligonucleotide probes may be immobilized at predefined locations on the a ⁇ ay. The resulting a ⁇ ay may be employed to screen for differences in organisms or samples or products containing genetic material as follows.
  • Genomic or cDNA libraries are prepared using techniques well known in the art.
  • the resulting target DNA is then labeled with a suitable marker, such as a radiolabel, chromophore, fluorophore or chemiluminescent agent, using protocols well known for those skilled in the art.
  • a solution of the labeled target DNA is contacted with the surface of the a ⁇ ay and incubated for a suitable period of time. The surface of the a ⁇ ay is then washed free of unbound target DNA and the probes to which the target DNA hybridized are determined by identifying those regions of the array to which the markers are attached.
  • the marker is a radiolabel, such as 2 P
  • autoradiography is employed as the detection method.
  • the marker is a fluorophore, such as fluorescein
  • the location of bound target DNA is determined by means of fluorescence spectroscopy.
  • Automated equipment for use in fluorescence scanning of oligonucleotide probe anays is available from Affymetrix, Inc. (Santa Clara, CA) and may be operated according to the manufacturer's instractions. Such equipment may be employed to determine the intensity of fluorescence at each predefined location on the anay, thereby providing a measure of the amount of target DNA bound at each location.
  • Such an assay would be able to indicate not only the absence and presence of the marker probe in the target, but also the quantitative amount as well.
  • oligonucleotide probe kits of the present invention may be employed to examine the presence/absence (or relative amounts in case of mixtures) of polynucleotides in different samples or products containing different materials rapidly and in a cost-effective manner.
  • microbial species which may be examined using the present invention, include lactic acid bacteria, such as Lactobacillus rhamnosus, and other microbial species.
  • Another aspect of the present invention involves collections of a plurality of polynucleotides of the present invention.
  • a collection of a plurality of the polynucleotides of the present invention may be recorded and/or stored on a storage medium and subsequently accessed for purposes of analysis, comparison, etc.
  • Suitable storage media include magnetic media such as magnetic diskettes, magnetic tapes, CD-ROM storage media, optical storage media, and the like.
  • Suitable storage media and methods for recording and storing information, as well as accessing information such as polynucleotide sequences recorded on such- media, are well known in the art.
  • the polynucleotide information stored on the storage medium is preferably computer-readable and may be used for analysis and comparison of the polynucleotide information.
  • the storage medium includes a collection of at least 20, preferably at least 50, more preferably at least 100, and most preferably at least 200 of the polynucleotides of the present invention, preferably the polynucleotides identified as SEQ ID NOS: 1-80, including variants of those polynucleotides.
  • Another aspect of the present invention involves a combination of polynucleotides, the combination containing at least 5, preferably at least 10, more preferably at least 20, and most preferably at least 50 different polynucleotides of the present invention, including polynucleotides selected from SEQ ID NOS: 1-80, and variants of these polynucleotides.
  • the present invention provides genetic constructs comprising, in the
  • a gene promoter sequence and an open reading frame coding for at least a functional portion of a polypeptide encoded by a polynucleotide of the present invention also comprise a gene termination sequence.
  • the open reading frame may be oriented in either a sense or antisense direction.
  • Genetic constructs comprising a non-coding region of a gene coding for a polypeptide encoded by an inventive polynucleotide or a nucleotide sequence complementary to a non-coding region, together with a gene promoter sequence, are also provided.
  • a terminator sequence may form part of this construct.
  • the gene promoter and termination sequences are functional in a host organism.
  • the gene promoter and termination sequences are common to those of the polynucleotide being introduced.
  • the genetic construct may further include a marker for the identification of transformed cells.
  • Techniques for operatively linking the components of the genetic constructs are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook et al, in Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratories Press: Cold Spring Harbor, NY, 1989.
  • the genetic constructs of the present invention may be linked to a vector having at least one replication system, for example, E. coli, whereby after each manipulation, the resulting construct can be cloned and sequenced and the co ⁇ ectness of the manipulation determined.
  • Transgenic microbial cells comprising the genetic constructs of the present invention are also provided by the present invention, together with microbes comprising such transgenic cells, products and progeny of such microbes, and materials including such microbes.
  • Techniques for stably incorporating genetic constructs into the genome of target microbes such as Lactobacillus species, Lactococcus lactis or E. coli, are well known in the art of bacterial transformation and are exemplified by the transformation of E. coli for sequencing described in Example 1.
  • Transgenic non-microbial cells comprising the genetic constructs of the present invention are also provided, together with orgamsms comprising such transgenic cells, and products and progeny of such organisms.
  • Genetic constracts of the present invention may be stably incorporated into the genomes of non-microbial target organisms, such as fungi, using techniques well known in the art.
  • the genetic constructs of the present invention are employed to transform microbes used in the production of food products, ingredients, processing aids, additives or supplements and for the production of microbial products for pharmaceutical uses, particularly for modulating immune system function and immunological effects, and in the production of chemoprotectants providing beneficial effects, probiotics and health supplements.
  • the inventive genetic constructs may also be employed to transform bacteria that are used to produce enzymes or substances such as polysaccharides, flavor compounds and bioactive substances, and to enhance resistance to industrial processes such as drying and to adverse stimuli in the human digestive system.
  • the genes involved in antibiotic production, and phage uptake and resistance in Lactobacillus rhamnosus are considered to be especially useful.
  • the target microbe to be used for transformation with one or more polynucleotides or genetic constructs of the present invention is preferably selected from the group consisting of bacterial genera Lactococcus, Lactobacillus, Streptococcus, Oenococcus, Lactosphaera, Trichococcus, Pediococcus and others potentially useful in various fermentation industries and is most preferably selected from the group consisting of the following Lactobacillus species: 5 Lactobacillus acetotolerans, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alimentarius, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus arizonae, Lactobacillus aviarius, Lac
  • Lactobacillus delbrueckii subsp. lactis, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus fructivorans, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus graminis, Lactobacillus hamsteri, Lactobacillus helveticus, Lactobacillus helveticus subsp.
  • Lactobacillus hetero Lactobacillus hilgardii, Lactobacillus homohiochii, Lactobacillus japonicus, Lactobacillus johnsonii, Lactobacillus kefiri, Lactobacillus lactis, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus mali, Lactobacillus maltaromicus, Lactobacillus manihotivorans, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus oris, Lactobacillus panis, Lactobacillus paracasei, Lactobacillus paracasei subsp.
  • the present invention provides methods for modifying the concentration, composition and/or activity of a polypeptide in a host organism, such as a microbe, comprising stably incorporating a genetic construct of the present invention into the genome of the host organism by ttansforming the host organism with such a genetic construct.
  • the genetic constracts of the present invention may be used to transform a variety of -organisms including plants, such as monocotyledonous angiosperms (e.g., grasses, corn, grains, oat, wheat and barley); dicotyledonous angiosperms (e.g., Arabidopsis, tobacco, legumes, alfalfa, oaks, eucalyptus, maple); gymnosperms, (e.g., Scots pine (Aronen, Finnish Forest Res. Papers, Vol.
  • monocotyledonous angiosperms e.g., grasses, corn, grains, oat, wheat and barley
  • dicotyledonous angiosperms e.g., Arabidopsis, tobacco, legumes, alfalfa, oaks, eucalyptus, maple
  • gymnosperms e.g., Scots pine (Aronen, Finnish Forest Res. Papers
  • transgenic plant cells comprising the genetic constructs of the present invention are provided, together with plants comprising such transgenic cells, and fruits, seeds, products and progeny of such plants.
  • Techniques for stably incorporating genetic constructs into the genome of target organisms are well known in the art and include Agrobacterium tumefaciens mediated introduction, electroporation, protoplast fusion, injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like.
  • the choice of technique wiU depend upon the target plant to be transformed. For example, dicotyledonous plants, and certain monocots and gymnosperms, may be transformed by Agrobacterium Ti plasmid technology, as described, for example by Bevan, Nucleic Acids Res. 12:8711-8721, 1984.
  • Targets for the introduction of the genetic constructs include tissues, such as leaf tissue, disseminated cells, protoplasts, seeds, embryos, meristematic regions, cotyledons, hypocotyls, and the like.
  • tissues such as leaf tissue, disseminated cells, protoplasts, seeds, embryos, meristematic regions, cotyledons, hypocotyls, and the like.
  • the polynucleotides of the present invention may be further employed as non- disruptive tags for marking organisms, particularly microbes. Other organisms may, however, be tagged with the polynucleotides of the present invention, including commercially valuable plants, animals, fish, fungi and yeasts. Genetic constructs comprising polynucleotides of the present invention may be stably introduced into an organism as heterologous, non-functional, non-disruptive tags. It is then possible to identify the origin or source of the organism at a later date by determining the presence or absence of the tag(s) in a sample of material. Detection of the tag(s) may be accomplished using a variety of conventional techniques, and will generally involve the use of nucleic acid probes.
  • Sensitivity in assaying the presence of probe can be usefully increased by using branched oligonucleotides, as described by Horn et al., Nucleic Acids Res. 25(23):4842-4849, 1997, enabling detection of as few as 50 DNA molecules in the sample.
  • Polynucleotides of the present invention may also be used to specifically suppress gene expression by methods that operate post-transcriptionally to block the synthesis of products of targeted genes, such as RNA interference (RNAi), and quelling.
  • RNAi RNA interference
  • traditional methods of gene suppression employing anti-sense RNA or DNA, operate by binding to the reverse sequence of a gene of interest such that binding interferes with subsequent cellular processes and therefore blocks synthesis of the conesponding protein.
  • RNAi also operates on a post- translational level and is sequence specific, but suppresses gene expression far more efficiently.
  • Exemplary methods for controUing or modif ing gene expression using RNAi are provided in WO 99/49029 and WO 99/53050. In these methods, post-transcriptional gene silencing is brought about by a sequence-specific RNA degradation process which results in the rapid degradation of transcripts of sequence-related genes. Studies have shown that double-stranded RNA may act as a mediator of sequence-specific gene silencing (see, for example, Montgomery and Fire, Trends in Genetics, 14:255-258, 1998). Gene constructs that produce transcripts with self-complementary regions are particularly efficient at gene silencing.
  • a unique feature of this post-transcriptional gene silencing pathway is that silencing is not limited to the cells where it is initiated.
  • the gene-silencing effects may be disseminated to other parts of an organism and even transmitted through the germ line to several generations.
  • the polynucleotides of the present invention may thus be employed to generate gene silencing constructs and/or gene-specific self-complementary RNA sequences that can be delivered by conventional art-known methods to cells, such as microbial cells.
  • sense and antisense sequences can be placed in regions flanking an intron sequence in proper splicing orientation with donor and acceptor splicing sites, such that intron sequences are removed during processing of the transcript and sense and antisense sequences, as weU as splice junction sequences, bind together to form double-stranded RNA.
  • spacer sequences of various lengths may be employed to separate self- complementary regions of sequence in the construct.
  • intron sequences are spliced-out, allowing sense and anti-sense sequences, as well as splice junction sequences, to bind forming double-stranded RNA.
  • the gene-specific double-stranded RNA segments are delivered to one or more targeted areas to be internalized into the cell cytoplasm to exert a gene silencing effect.
  • the double-stranded RNA must have sufficient homology to the targeted gene to mediate RNAi and is preferably at least 25 nucleotides in length.
  • Gene silencing RNA sequences comprising the polynucleotides of the present invention are useful for creating genetically modified organisms, such as microbes, with desired phenotypes as well as for characterizing genes (for example, in high-throughput screening of sequences), and stadying their functions in intact organisms.
  • the present invention provides methods for using one or more of the inventive polypeptides or polynucleotides to treat disorders in a mammal, such as a human.
  • the polypeptide or polynucleotide is generaUy present within a composition, such as a pharmaceutical or immunogenic composition.
  • compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier.
  • Immunogenic compositions may comprise one or more of the above polypeptides and an immunostimulant, such as an adjuvant or a liposome, into which the polypeptide is incorporated.
  • a composition of the present invention may contain DNA encoding one or more polypeptides described herein, such that the polypeptide is generated in situ.
  • the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, and bacterial and viral expression systems.
  • Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminator signal).
  • Bacterial delivery systems involve the administration of a bacterium (such as Bacillus Calmette-Guerin) that expresses an immunogenic portion of the polypeptide on its cell surface.
  • the DNA may be introduced using a viral expression system (e.g., vaccinia or other poxvirus, retrovirus, or adenovirus), which may involve the use of a non- pathogenic, or defective, replication competent virus.
  • vaccinia or other poxvirus, retrovirus, or adenovirus e.g., vaccinia or other poxvirus, retrovirus, or adenovirus
  • the DNA may also be "naked," as described, for example, in Ulmer et al, Science 259: 1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993.
  • the uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.
  • any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration.
  • the carrier preferably comprises water, saline, alcohol, a lipid, a wax or a buffer.
  • any of the above carriers or a solid carrier such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed.
  • Biodegradable microspheres e.g., polylactic galactide
  • Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109. Any of a variety of adjuvants may be employed in the immunogenic compositions of the present invention to non-specifically enhance an immune response.
  • adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a non-specific stimulator of immune responses, such as lipid A, Bordetella pertussis or M. tuberculosis.
  • Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, MI), and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ).
  • Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A and Quil A. Routes and frequency of administration, as well as dosage, vary from individual to individual.
  • inventive compositions may be administered by injection (e.g., intradermal, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally.
  • amount of polypeptide present in a dose ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg per kg of host, and preferably from about 100 pg to about 1 ⁇ g per kg of host.
  • Suitable dose sizes will vary with the size of the patient, but wiU typically range from about 0.1 ml to about 2 ml.
  • Example 1 ISOLATION AND CHARACTERIZATION OF DNA SEQUENCES FROM LACTOBACILLUS RHAMNOSUS STRAIN HNOOl Lactobacillus rhamnosus strain HNOOl DNA libraries were constructed and screened as follows. DNA was prepared in large scale by cultivating the bacteria in 2 x 100 ml cultures with 100 ml MRS broth (Difco Laboratories, Detroit MI) and 1 ml Lactobacillus glycerol stock as inoculum, placed into 500 ml culture flasks and incubated at 37 °C for approx. 16 hours with shaking (220 rpm). The cultures were centrifuged at 3500 rpm for 10 min to pellet the cells.
  • the supernatant was removed and the cell pellet resuspended in 40 ml fresh MRS broth and transfened to clean 500 ml culture flasks.
  • Fresh MRS broth 60 ml was added to bring the volume back to 100 ml and flasks were incubated for a further 2 hrs at 37°C with shaking (220 rpm).
  • the cells were pelleted by centrifugation (3500 rpm for 10 min) and supernatant removed. Cell pellets were washed twice in 20 ml buffer A (50 mM NaCl, 30 mM Tris pH 8.0, 0.5 mM EDTA).
  • TEN buffer (1M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA) and sterile filtered. Duutions of 5, 10, 15, 20, 25, 30, 35 and 40% sucrose were prepared and overlaid carefully in Beckman Polyallomer tubes, and kept overnight at 4°C.
  • TEN buffer (4 ml) was loaded onto the gradient, with 3 ml of DNA solution on top. The gradients were centrifuged at 26K for 18 hours at 4°C in a Centricon T-2060 centrifuge using a Kontron TST 28-38 rotor. After deceleration without braking (approx.
  • DNA was pelleted at top speed in a microcentrifuge for 15 min, washed with 70% ethanol and pelleted again, dried and resuspended in 10 ⁇ l TE buffer.
  • DNA was ligated into dephosphorylated -S ⁇ TwHI-digested pBluescript SK if and dephosphorylated BamHI- ⁇ igested lambda ZAP Express using standard protocols.
  • Packaging of the DNA was done using Gigapack III Gold packaging extract (Stratagene, La Jolla, CA) following the manufacturer's protocols. Packaged libraries were stored at 4 °C. Mass excision from the primary packaged phage library was done using XLI -Blue
  • the excised phagemids were diluted with NZY broth (Gibco BRL, Gaithersburg, MD) and plated out onto LB-kanamycin agar plates containing 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside (X-gal) and isopropylthio-beta- galactoside (EPTG). After incubation, single colonies were picked for PCR size determination before the most suitable libraries were selected for sequencing. Of the colonies picked for DNA rriinipreps and subsequent sequencing, the large majority contained an insert suitable for sequencing.
  • the sequence of the genomic DNA fragments was determined using a Perkin Elmer/Applied Biosystems Division Prism 377 sequencer.
  • the DNA clones were sequenced from the 5' and/or 3' end, and are identified as SEQ ED NOS: 1-80 disclosed herein. This example not only shows how the sequences were obtained, but also that a bacterium (E. coli) can be stably transformed with any desired DNA fragment of the present invention for permanent marking for stable inheritance.
  • BLASTN Polynucleotide Analysis The determined DNA sequences were compared to and aligned with known sequences in the public databases.
  • polynucleotides identified in S ⁇ Q ID NO: 1-80 were compared to polynucleotides in the ⁇ MBL database as of August 12, 2002, using BLASTN algorithm Version 2.0.11 [Jan-20-2000], set to the following running parameters: Unix running command: blastall -p blastn -d embldb -e 10 -G 0 - ⁇ 0 -r 1 -v 30 -b 30 -i queryseq -o results. Multiple alignments of redundant sequences were used to build up reliable consensus sequences.
  • the cDNA sequences of S ⁇ Q ID NOS: 1-32 and 34-80 were determined to have less than 60% identity, determined as described above, to sequences in the ⁇ MBL database using the computer algorithm BLASTN, as described above.
  • the predicted amino acid sequences of SEQ ID NOS: 87, 139 and 176-179 were determined to have less than 90% identity, determined as described above, to sequences in the SWISSPROT-TrEMBLE database using the computer gorithm BLASTP, as described0 above.
  • the predicted amino acid sequences of SEQ JJD NOS: 117, 118 and 126 were determined to have less than 98% identity, determined as described above, to sequences in the SWISSPROT-TrEMBLE database using the computer algorithm BLASTP, as described above.
  • BLASTX Polynucleotide Analysis The isolated cDNA sequences were compared to sequences in the SwissProt- TrEMBLE protein databases using the computer gorithm BLASTX.
  • the cDNA sequences of SEQ ID NOS: 1-14, 16-49, 52-58, 60-72, 74-78 and 80 were determined to have less than 50% identity, determined as described above, to sequences in the SWISSPROT-TrEMBLE database using the computer algorithm BLASTX, as described above.
  • the cDNA sequences of SEQ ID NOS: 15, 50, 51, 59, 73 and 79 were determined to have less than 75% identity, deterrnined as described above, to sequences in the SWISSPROT- TrEMBLE database using BLASTX, as described above.
  • the isolated polynucleotides of the present invention identified as SEQ ID NOS: 1-80 were putatively identified as encoding polypeptides having similarity to the polypeptides shown above in Table 1.
  • the amino acid sequences encoded by the DNA sequences of SEQ ID NO: 1-80 are provided in SEQ ID NO: 81-183, respectively.
  • Several of the sequences provided in SEQ ID NO: 1-80 were found to be full-length and to contain open reading frames (ORFs). These full-length sequences, the location of ORFs (by nucleotide position) contained within these sequences, and the co ⁇ esponding amino acid sequences are provided in Table 2 below.
  • the full-length polynucleotide sequence of the deoD purine nucleoside phosphorylase gene AQ1 from L. rhamnosus HNOOl is given in SEQ ID NO: 78 and shown in Fig. 1 (with ATG initiation and translation stop codons boxed).
  • the polypeptide sequence of AQ1 is given in SEQ LO NO: 181 and shown in Fig. 2.
  • a 634 bp internal AQ1 fragment was amplified by PCR using standard laboratory protocols.
  • the nucleotide sequences of the oligonucleotide primers are given in SEQ ID NOS: 184 and 185. The fragments were cloned into the pBEryl vector cut with Sma ⁇ .
  • the 3.6 kb pBEryl vector was constructed using the replicon and multiple cloning site (MCS) from the phagemid pBlueScript (pBS-SK+) (Stratagene, La Jolla CA, USA).
  • MCS replicon and multiple cloning site
  • pBS-SK+ phagemid pBlueScript
  • the ampicUlin resistance gene in pBS-SK+ was removed by digestion with Real (Roche, Auckland, New Zealand), and the 1,953 bp fragment containing the ColEl origin and multiple cloning site purified and treated with Klenow enzyme (Roche) to give a blunt-ended fragment.
  • a gene encoding resistance to erythromycin (Em) was isolated on a 1.6 kb fragment obtained after cutting pVA891 (Macrina et al, Gene 25:145-50, 1983) with Clal and indE ⁇ and treatment with Klenow to give blunt ends.
  • the 1.6 kb Em fragment was ligated to the 1,953 bp pBS-SK+ fragment, transformed into E. coli TGI (Gibson TJ, Studies on the Epstein-Barr virus genome. Ph.D. Thesis, University of Cambridge, Cambridge, England, 1984), and plated on LB agar plates containing 200 ⁇ g ml Em.
  • Colonies giving PCR patterns consistent with the insertional inactivation of the endogenous HNOOl deoD purine nucleoside phosphorylase AQl gene were assessed for increased resistance to UV irradiation. Briefly, single colonies of wild-type of AQl -knockout HNOOl strains were inoculated into 5 ml MRS, incubated aerobically overnight at 37 °C, and 0.1 ml then used to inoculate a 10 ml MRS culture. Cultures were grown to log phase (i.e. an OD ⁇ oo of approximately 0.3) at 37 °C, and then 5 ml of culture taken and cells collected by centrifugation.
  • UV light compared to wild-type HNOOl UV light compared to wild-type HNOOl. UV light exposure of 20 seconds appeared to have no effect o xAQl ' viability while the viabUity of wild-type HNOOl cells had dropped to 34.7%.
  • HNOOl deoD purine nucleoside phosphorylase (EC 2.4.2.1) is involved in the purine biosynthesis and salvage pathways. Its role in maintaining intracellular guanosine pools suggests that it may be involved in resistance to a number of stress conditions mcluding UV light exposure, as well as high salt, pH and temperature (Duwat et al, Int J Food Microbiol. 55:83-6, 2000).
  • Applications for HNOOl purine nucleoside phosphorylase AQl include: • methods of enhanced survival of industrial processes; • improved colonization of human intestinal environment; and • improved survival of multiple stress conditions.
  • the full-length polynucleotide sequence of the relA GTP pyrophosphokinase gene AMI from L. rhamnosus HNOOl is given in SEQ ID NO: 79 and shown in Fig. 4 (with ATG initiation and translation stop codons boxed).
  • the polypeptide sequence of AMI is given in SEQ TD NO: 182 and shown in Fig. 5.
  • a 798 bp internal AMI fragment was amplified by PCR using standard laboratory protocols.
  • the nucleotide sequences of the oligonucleotide primers are given in SEQ ID NOS: 186 and 187. The fragments were cloned into the pBEryl vector cut with Smal, as described in Example 2.
  • the resulting pBEryl construct encoding the HNOOl relA GTP pyrophosphokinase AMI gene was transformed into competent HNOOl cells and grown anaerobicaUy for 48 hrs at 37 °C on MRS lactobacilli agar (Difco, Detroit MI) containing 2.5 ⁇ g ml Em.
  • Em-resistant HNOOl were checked for integration of the plasmid construct into the relA gene by PCR using vector-specific (T3 or T7) and AMI internal fragment-specific primers. Colonies giving PCR patterns consistent with the insertional inactivation of the endogenous HNOOl relA GTP pyrophosphokinase AMI gene, were assessed for increased resistance to UV inadiation as described in Example 2.
  • Fig. 6 shows the results of a UV light exposure assay measuring relative viability in response to increasing doses of UV light in AMI ' HNOOl ( ⁇ ) and wild-type HNOOl ( ⁇ ) strains. Results indicate that the AMI " HNOOl mutant strain showed enhanced survival to exposure to UV light compared to wild-type HNOOl. UV light exposure of 20 seconds appeared to have little effect on AMI " cell viability (91.7%) while the viability of wild-type HNOOl cells had dropped to 34.7%. After 30 seconds UV hght exposure, 61.1% of AMI ' cells survived compared to only 27.9% for wild type.
  • GTP pyrophosphokinase or (EC 2.7.6.5) produces guanosine 3 '-diphosphate 5'- triphosphate, a marker of the "stringent response", a regulatory state induced in bacteria by nutrient starvation and other environmental stresses (reviewed in Chatterji and Ojha, Curr Opin Microbiol. 4:160-5, 2001).
  • GTP pyrophosphokinase relA gene expression improved the resistance to a number of stress conditions including UV light exposure, as well as high salt, pH and temperature, in Lactococcus lactis (Duwat et al, Int J. Food Microbiol. 55:83-6, 2000).
  • Applications for HNOOl GTP pyrophosphokinase AMI include: • methods of enhanced survival of industrial processes; • improved colonization of human intestinal environment; and • improved survival of Lactobacilli to multiple stress conditions.
  • SEQ ID NOS: 1-187 are set out in the attached Sequence Listing. The codes for nucleotide sequences used in the attached Sequence Listing, including the symbol "n," conform to WLPO Standard ST.25 (1998), Appendix 2, Table 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nouveaux polynucléotides isolés dans lactobacillus rhamnosus, ainsi que des sondes oligonucléotidiques et des amorces, des constructions génétiques comprenant les polynucléotides, des matières biologiques, dont des plantes, des micro-organismes et des organismes multicellulaires comprenant les polynucléotides, les polypeptides exprimés par les polynucléotides, ainsi que des méthodes d'utilisation des polynucléotides et polypeptides.
PCT/NZ2003/000278 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation WO2005056801A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03781132A EP1711609A1 (fr) 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans i lactobacillus rhamnosus hn001 /i , matieres les contenant et leurs methodes d'utilisation
AU2003288826A AU2003288826A1 (en) 2003-12-15 2003-12-15 Polynucleotides and polypeptides isolated from lactobacillus rhamnosus hn001 materials incorporating them and methods for using them
CA002549710A CA2549710A1 (fr) 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation
PCT/NZ2003/000278 WO2005056801A1 (fr) 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NZ2003/000278 WO2005056801A1 (fr) 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation

Publications (1)

Publication Number Publication Date
WO2005056801A1 true WO2005056801A1 (fr) 2005-06-23

Family

ID=34676056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2003/000278 WO2005056801A1 (fr) 2003-12-15 2003-12-15 Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation

Country Status (4)

Country Link
EP (1) EP1711609A1 (fr)
AU (1) AU2003288826A1 (fr)
CA (1) CA2549710A1 (fr)
WO (1) WO2005056801A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099875A1 (fr) * 2010-02-15 2011-08-18 Salmon, Bernadette Utilisation de bactéries lactiques pour traiter ou prévenir la rhinite

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694766A1 (fr) * 1992-08-13 1994-02-18 Agronomique Inst Nat Rech Clônage du gène de structure d'une aminopeptiddase de lactococcus lactis, production et utilisations de ladite aminopeptidase.
EP0633316A1 (fr) * 1993-07-01 1995-01-11 European Economic Community E.E.C. Lys aminopeptidase PepN de Lactobacillus delbrückii ssp. lactis, acides nucléiques la codant et son utilisation dans des procédés de fermentation
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001077334A2 (fr) * 2000-04-11 2001-10-18 Institut National De La Recherche Agronomique Genome de lactococcus lactis, polypeptides et utilisations
US20030138822A1 (en) * 1999-08-13 2003-07-24 Genesis Research And Development Corp. Ltd. Polynucleotides and polypeptides, materials incorporating them and methods for using them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694766A1 (fr) * 1992-08-13 1994-02-18 Agronomique Inst Nat Rech Clônage du gène de structure d'une aminopeptiddase de lactococcus lactis, production et utilisations de ladite aminopeptidase.
EP0633316A1 (fr) * 1993-07-01 1995-01-11 European Economic Community E.E.C. Lys aminopeptidase PepN de Lactobacillus delbrückii ssp. lactis, acides nucléiques la codant et son utilisation dans des procédés de fermentation
US20030138822A1 (en) * 1999-08-13 2003-07-24 Genesis Research And Development Corp. Ltd. Polynucleotides and polypeptides, materials incorporating them and methods for using them
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001077334A2 (fr) * 2000-04-11 2001-10-18 Institut National De La Recherche Agronomique Genome de lactococcus lactis, polypeptides et utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE DGENE [online] 11 January 2001 (2001-01-11), Database accession no. ABG24207 *
DATABASE DGENE [online] 18 February 1994 (1994-02-18), Database accession no. AAR56658 *
DATABASE GENBANK [online] 13 September 2001 (2001-09-13), HOSKINS J.A. ET AL: "Aminopeptidase [Streptococcus pneumoniae R6]", Database accession no. AAK99058 *
DATABASE GENBANK [online] 21 February 2003 (2003-02-21), KLEEREBEZEM M. ET AL: "cysteine aminopeptidase [Lactobacillus plantarum WCFS1]", Database accession no. CAD63213 *
DATABASE GENBANK [online] 21 February 2003 (2003-02-21), KLEEREBEZUM M. ET AL: "membrane alanine aminopeptidase [Lactobacillus plantarum WCFS1]", Database accession no. CAD63500 *
DATABASE GENBANK [online] 23 September 2003 (2003-09-23), "Aminopeptidase C [Lactobacillus gasseri] NCBI Microbial Genomes Anotation Project", Database accession no. ZP_00047124 *
DATABASE GENBANK [online] 27 September 2003 (2003-09-27), "Leucyl aminopeptidase (aminopeptidase T) [Enterococcus faecium] NCBI Microbial Genomes Annotation Project", Database accession no. ZP_00037807 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099875A1 (fr) * 2010-02-15 2011-08-18 Salmon, Bernadette Utilisation de bactéries lactiques pour traiter ou prévenir la rhinite

Also Published As

Publication number Publication date
CA2549710A1 (fr) 2005-06-23
AU2003288826A1 (en) 2005-06-29
EP1711609A1 (fr) 2006-10-18

Similar Documents

Publication Publication Date Title
US7125698B2 (en) Polynucleotides, materials incorporating them, and methods for using them
US7052896B2 (en) Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
US6476209B1 (en) Polynucleotides, materials incorporating them, and methods for using them
AU2001284558A1 (en) Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
US7824894B2 (en) Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
US7026463B2 (en) Polynucleotides and polypeptides, materials incorporating them and methods for using them
US6544772B1 (en) Polynucleotides, materials incorporating them, and methods for using them
CN113677799A (zh) 一种遗传修饰乳酸杆菌及其应用
US7754868B2 (en) Nucleic acid encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor
US20050202437A1 (en) Polynucleotides and polypeptides, materials incorporating them and methods for using them
WO2005056801A1 (fr) Polynucleotides et polypeptides isoles dans lactobacillus rhamnosus hn001, matieres les contenant et leurs methodes d'utilisation
US20060099623A1 (en) Polynucleotides and polypeptides isolated from lactobacillus and methods for their use
JP2000505642A (ja) 非病原性微生物の新規接着因子および特定の共生的性質について微生物をスクリーニングするためのその適用；そのような微生物と接着因子とを含む新規薬剤学的組成物および食品添加物
JP2007530034A (ja) 新規のマンノース特異的アドヘシンとその使用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005511698

Country of ref document: JP

Ref document number: 2549710

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2003288826

Country of ref document: AU

Ref document number: 548464

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003781132

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003781132

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2003781132

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003781132

Country of ref document: EP